CURRICULUM VITAE
                                                                                  February 19, 2005
Name:...
2002           University of Pittsburgh                    Mini-MBA Business Essentials
               Pittsburgh, PA     ...
2002                 Metacine, Incorporated                     Chief Scientific Officer, Cofounder
                      ...
American Surgical Association
Association for Academic Surgery
Cell Transplant Society
Central Surgical Association
Clinic...
EDITORIAL BOARDS

1988 European Cytokine Journal
1990 J. Immunotherapy (Formerly J. Biological Response Modifiers, Assoc. ...
ACTIVITIES

1983-1990   Hospital Infection Control Committee, NIH

1984        Member, Source Evaluation Group RFP NCI CM ...
Mechanisms and Therapy of Childhood Diseases"

1991          Chairperson, Minisymposium on Antitumor Effectors; FASEB,Wash...
Stage IV Melanoma; John Wayne Cancer Institute; August 5, 1997.

1997-2000   Cardinal Bernardin Cancer Center External Adv...
2002   Amer. Association for Gene Therapy; Meet the Professor Session – Immunology

2002   James Ewing Young Investigator ...
2004-2006   Scientific Programs Committee ASCO

2004        NCI Study Section, Strategic Partnersing to Evaluate Cancer Si...
1993   Organizer, Symposium Molecules to Medicine, 2nd Inter. Congress on Biol.
       Response Modifiers; San Diego, CA; ...
1998        Coorganizer, 13th Society for Biological Therapy Meeting, Pittsburgh; October
            21-21, 1998.

1998-2...
2004   Ad Hoc Member, Clinical Oncology Study Section, NCI




                                 13
REGULATORY EXPERIENCE WITH FDA/RAC/IRBS


1979   TCGF Expanded Lymphocytes for Cancer [Clinical Center, NIH]
       111
19...
Research Grants

9/92-10/96    NIH 1UO1 CA 58272-01 "Locoregional ALT with autologous IL-2, activated NK
              cel...
7/97-6/02           NIH NCI 1PO1DE12321-01. “Vaccine Development for Oral Carcinoma.”
                    Principal Invest...
Coinvestigator, Michael Lotze; 5% + technical support 50%; $1,843,745

10/01/04   NIDDK; Chronic Inflammation of the Liver...
PATENTS


Storkus Walter, Michael T. Lotze. Rapid Isolation of T-cells Epitopes from viable cells by mild acid
elusion. (N...
BOOKS

1990   Cellular Immunity and the Immunotherapy of Cancer, Ed. Lotze MT, Finn OJ, Wiley-Liss; New
       York, 1990....
SCIENTIFIC ADVISORY BOARDS

1990-1994      Cellco, Inc. Rockville, MD; Hollow-fiber growth of cells

1995-1998      Canji,...
MARATHONS
1985   Marine Corps
1990   Pittsburgh
1993   Pittsburgh
1998   Pittsburgh, Bordeaux [Marathon des Chateaux du Me...
BIBLIOGRAPHY

1.    Lotze, M.T., Strausser, J.L., Rosenberg, S.A. In vitro growth of cytotoxic human lymphocytes.
      II...
l3.   Harvey, J., Lotze, M.T., Bias, W.B., Hsu, S., Arnett, F.C., Stevens, M.B.: Rheumatoid arthritis in
      a Chippewa ...
26.   Rayner, A.A., Grimm, E.A., Lotze, M.T., Rosenberg, S.A.: Demonstration of shared recognition
      and lysis of auto...
39.   Lotze, M.T.: Stemming Cancer in the 80's. AIDS: A surgeon's responsibility. Bulletin of the
      American College o...
52.   Lotze, M.T., Carrasquillo, J.A., Weinstein J.N., Bryant, G.J., Perentesis, P., Reynolds, J.C.,
      Matis, L.A., Eg...
64.   Denicoff, K.D., Rubinow, D.R., Papa, M.Z., Simpson, C., Seipp, C.A., Lotze, M.T., Chang,
      A.E., Rosenstein, D.,...
77.   Skibber, J.M,., Matter, G.J., Pizzo, P.A., Lotze, M.T. Right lower quadrant pain in young
      patients with leukem...
89.   Schwartzentruber, D., Lotze, M.T., Rosenberg, S.A.: Colonic perforation: An unusual
      complication of therapy wi...
100.   Jablons, D.M., McIntosh, J.K., Mule, J.J., Nordan, J.J., Rudikiff, S., and Lotze, M.T.: Induction
       of Interfe...
112.   Rubin, J.T., Elwood, L., Rosenberg, S.A., Lotze, M.T.: Immunohistochemical Correlates of
       Response to Recombi...
applications. Human Immunology, 28:198-207, 1990.

124.   Lotze, M.T., Jablons, D.M., Rubin, J.T., Chang, A.E., Rosenberg,...
136.   Rosenberg, S.A., Aebersold, P., Cornetta, K., Kasid, A., Morgan, R.A., Moen, R., Karson, E.M.,
       Lotze, M.T., ...
149.   Lotze MT. Sui Generis (journal review article). Nature 1991.

150.   Lotze MT. Role of IL-4 in the antitumor respon...
Phase I Study. J Clin Onc, 10: 1643-1649, 1992.

163.   Rubin JT, Duquesnoy R, Day R, Simonis TB, Rosenberg SA and Lotze M...
36
175.   Tahara H, Zeh H, Storkus WJ, Pappo I, Watkins S, Gately MK, Gubler U, Wolf SF, Robbins PD
       and Lotze MT. Fibr...
189.   Irshaid Y, Adedoyin A, Lotze M, Branch R. Monoacetyldapsone inhibition of dapsone
       hydroxylation by human and...
202.   Maeurer MJ, Storkus WJ, Lotze MT. Tumor Vaccines. Principles of Clinical Immunology,
       Robert Rich, Editor, 19...
213.   Storkus WJ, Lotze MT. Biology of Tumor Antigens. B. Tumor Antigens Recognized by Immune Cells.
       In Biologic T...
226.   Suzuki T, Tahara H, Robbins P, Narula S, Moore K, Lotze MT. The human herpes virus 4 cIL-
       10 homologue, vIL-...
238.   Maeurer MJ, Gollin S, Storkus WJ, Swaney W, Martin D, Castelli C, Salter R, Knuth A, Lotze
       MT. Tumor escape ...
251.   Pappo I, Lotze MT. Immunotherapy of lung cancer. In Landreneau R, editor. Thoracic Surgery,
       in press.

252. ...
264.   Dookeran KA, Lotze MT, Sikora SS, Rao UNM. Pancreatic and periampullary carcinomas with
       epididymo-orchidic m...
CURRICULUM VITAE February 19, 2005 Name: Michael T. Lotze, M ...
CURRICULUM VITAE February 19, 2005 Name: Michael T. Lotze, M ...
CURRICULUM VITAE February 19, 2005 Name: Michael T. Lotze, M ...
CURRICULUM VITAE February 19, 2005 Name: Michael T. Lotze, M ...
CURRICULUM VITAE February 19, 2005 Name: Michael T. Lotze, M ...
CURRICULUM VITAE February 19, 2005 Name: Michael T. Lotze, M ...
CURRICULUM VITAE February 19, 2005 Name: Michael T. Lotze, M ...
CURRICULUM VITAE February 19, 2005 Name: Michael T. Lotze, M ...
CURRICULUM VITAE February 19, 2005 Name: Michael T. Lotze, M ...
CURRICULUM VITAE February 19, 2005 Name: Michael T. Lotze, M ...
CURRICULUM VITAE February 19, 2005 Name: Michael T. Lotze, M ...
CURRICULUM VITAE February 19, 2005 Name: Michael T. Lotze, M ...
CURRICULUM VITAE February 19, 2005 Name: Michael T. Lotze, M ...
CURRICULUM VITAE February 19, 2005 Name: Michael T. Lotze, M ...
CURRICULUM VITAE February 19, 2005 Name: Michael T. Lotze, M ...
CURRICULUM VITAE February 19, 2005 Name: Michael T. Lotze, M ...
CURRICULUM VITAE February 19, 2005 Name: Michael T. Lotze, M ...
CURRICULUM VITAE February 19, 2005 Name: Michael T. Lotze, M ...
CURRICULUM VITAE February 19, 2005 Name: Michael T. Lotze, M ...
CURRICULUM VITAE February 19, 2005 Name: Michael T. Lotze, M ...
CURRICULUM VITAE February 19, 2005 Name: Michael T. Lotze, M ...
CURRICULUM VITAE February 19, 2005 Name: Michael T. Lotze, M ...
CURRICULUM VITAE February 19, 2005 Name: Michael T. Lotze, M ...
CURRICULUM VITAE February 19, 2005 Name: Michael T. Lotze, M ...
CURRICULUM VITAE February 19, 2005 Name: Michael T. Lotze, M ...
CURRICULUM VITAE February 19, 2005 Name: Michael T. Lotze, M ...
CURRICULUM VITAE February 19, 2005 Name: Michael T. Lotze, M ...
CURRICULUM VITAE February 19, 2005 Name: Michael T. Lotze, M ...
CURRICULUM VITAE February 19, 2005 Name: Michael T. Lotze, M ...
CURRICULUM VITAE February 19, 2005 Name: Michael T. Lotze, M ...
CURRICULUM VITAE February 19, 2005 Name: Michael T. Lotze, M ...
CURRICULUM VITAE February 19, 2005 Name: Michael T. Lotze, M ...
CURRICULUM VITAE February 19, 2005 Name: Michael T. Lotze, M ...
CURRICULUM VITAE February 19, 2005 Name: Michael T. Lotze, M ...
CURRICULUM VITAE February 19, 2005 Name: Michael T. Lotze, M ...
CURRICULUM VITAE February 19, 2005 Name: Michael T. Lotze, M ...
CURRICULUM VITAE February 19, 2005 Name: Michael T. Lotze, M ...
CURRICULUM VITAE February 19, 2005 Name: Michael T. Lotze, M ...
CURRICULUM VITAE February 19, 2005 Name: Michael T. Lotze, M ...
CURRICULUM VITAE February 19, 2005 Name: Michael T. Lotze, M ...
CURRICULUM VITAE February 19, 2005 Name: Michael T. Lotze, M ...
CURRICULUM VITAE February 19, 2005 Name: Michael T. Lotze, M ...
CURRICULUM VITAE February 19, 2005 Name: Michael T. Lotze, M ...
CURRICULUM VITAE February 19, 2005 Name: Michael T. Lotze, M ...
CURRICULUM VITAE February 19, 2005 Name: Michael T. Lotze, M ...
CURRICULUM VITAE February 19, 2005 Name: Michael T. Lotze, M ...
CURRICULUM VITAE February 19, 2005 Name: Michael T. Lotze, M ...
CURRICULUM VITAE February 19, 2005 Name: Michael T. Lotze, M ...
CURRICULUM VITAE February 19, 2005 Name: Michael T. Lotze, M ...
CURRICULUM VITAE February 19, 2005 Name: Michael T. Lotze, M ...
CURRICULUM VITAE February 19, 2005 Name: Michael T. Lotze, M ...
Upcoming SlideShare
Loading in...5
×

CURRICULUM VITAE February 19, 2005 Name: Michael T. Lotze, M ...

4,047

Published on

Published in: Education, Health & Medicine
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
4,047
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
8
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

CURRICULUM VITAE February 19, 2005 Name: Michael T. Lotze, M ...

  1. 1. CURRICULUM VITAE February 19, 2005 Name: Michael T. Lotze, M.D. Birth Date: July 11, 1952 Home 5134 Westminster Place Birth Place: Altadena, CA Address: Pittsburgh, PA 15232 Citizenship: U.S.A. Home Phone: 412-682-1514 Social Security: on request Business Professor Surgery, Molecular Genetics and Biochemistry; Bioengineering University of Pittsburgh Medical School Address: University of Pittsburgh Molecular Medicine Institute Spouse: Joan Harvey, M.D. Rm 411, 300 Technology Dr. June 25, 1977 Pittsburgh, PA 15219 Children: Thomas, 3/30/79 Anna, 6/1/81 Business: 412-478-3316 (mobile) 412-624-3212; 383-9700 Main Office Michael, 11/3/83 Phone: 412-623- 7713 (admin) 412-624-8121 Inner Office Jenette, 11/24/88 412-692-2520 (Surgical Oncology); 412-383-9760 [MMI] Main office +1-412-383-9700 Fax: +1-412-383-9710 E-mail Addresses: LotzeMT@upmc.edu [preferred]; ltzmichaelt@aol.com; EDUCATION AND TRAINING Undergraduate 1969-1973 Northwestern University B. Medical Sciences Evanston, IL Graduate 1971-1974 Northwestern University Medical School, M.D. (Honors Program in Chicago, IL Medical Education) Postgraduate 1975 M. D. Anderson Tumor Institute Jr Medical Fellow, Surgery Houston, TX 1975-1976 Strong Memorial Hospital Intern/Resident, Surgery Rochester, NY 1976-1977 Strong Memorial Hospital Assistant Resident, Rochester, NY Surgery 1978-1980 National Cancer Institute Staff Fellow, Surgery Bethesda, MD Branch 1980-1982 University of Rochester Sr. & Chief Resident, Surgery Rochester, NY 1
  2. 2. 2002 University of Pittsburgh Mini-MBA Business Essentials Pittsburgh, PA for the Bio-Scientist 2002 ProteinChip University Ciphergen ProteinChip Technology Protein Profiling Advanced Course; July 26, 2002 APPOINTMENTS AND POSITIONS Academic 1972 University of Muenster, Westphalen Res. Asst. Physiologische Institut II West Germany Biochemistry Bovine Fibrinogen 1975 Twelve Oaks Hospital Emergency Room Physician Houston, TX 1980-1982 University of Rochester Instructor in Surgery 1983-1988 Uniformed Services University Assistant Professor of Health Bethesda, MD Sciences 1988-1990 Uniformed Services University Associate Professor of Of the Health Sciences, Bethesda, MD Surgery 1990-Present University of Pittsburgh Professor of Surgery, Molecular Pittsburgh, PA Genetics and Biochemistry; 1990-2000 Chief, Section of Surgical Oncology; made a Division in 1998 1991-2000 Pittsburgh Genetics Institute Codirector, Human Gene Pittsburgh, PA Therapy Program 1992-2000 Pittsburgh Cancer Institute Codirector, Division of Pittsburgh, PA Biological Therapeutics 1995-Current Pittsburgh Biotechnology, Inc CEO and President 1999-2001 SmithKline Beecham Pharmaceuticals Vice President and Director, Division of Inflammation, Tissue Repair & Oncology World Wide Discovery Biology; Research and Development 2001 GlaxoSmithKline Pharmaceuticals Vice President and Director, High Throughput Biology; Discovery Research Biology; Research and Development 2
  3. 3. 2002 Metacine, Incorporated Chief Scientific Officer, Cofounder Sr. VP for Medical Affairs 2002 University of Pittsburgh Director, Translational Research Molecular Medicine Institute 2002 University of Pittsburgh Professor of Bioengineering School of Engineering, Dept Bioengineering 2004 University of Pittsburgh Member McGowen Institute for Regenerative Medicine GOVERNMENT 1977-1978 National Health Service Corps Medical Officer Onamia, MN 1982-1990 National Cancer Institute Senior Investigator, Bethesda, MD Surgery Branch CERTIFICATION AND LICENSURE Speciality Certification 1983 American Board of Surgery #29138 Surgery 1993 American Board of Surgery, Recertification #29138 Surgery MEDICAL OR OTHER PROFESSIONAL LICENSURE 1975 National Board of Medical Examiners Diplomate 1976 New York 129152 1977 Minnesota 23584 1979 Maryland D23864 1990 Pennsylvania MD-042025-L MEMBERSHIP IN PROFESSIONAL AND SCIENTIFIC SOCIETIES American College of Surgeons, Fellow American Medical Association American Association of Cancer Research 1991 Program Committee American Association of Immunology 1990, 1992 Program Committee 1996/97 Comoderator Tumor Immunology Minisymposium 1997-2000 Tumor Immunology Block Cochair American Society of Clinical Oncology 1996/97 Program Committee 2004/2005 Biologic Therapeutics Program Committee 3
  4. 4. American Surgical Association Association for Academic Surgery Cell Transplant Society Central Surgical Association Clinical Immunology Society 1993 Program Committee 2001-2004 Federation of Clinical Immunology Societies, SBT Representative International Society for Biologic Therapy of Cancer 1991-1993 Program Committee 1994-Present Executive Council 1996-1998 Vice President and President Elect 1998-2000 President 2003 Chair, Cancer Biometrics Workshop 2004 Chair, Cancer Biometrics Session 2004-Present Collaboration Committee Melanoma Research Foundation 1996-Present Board of Directors Molecular Medicine Society Society for Analytical Cytology Society of Biologic Screening, 2001 Society of Surgical Oncology 1992,1993 Program Committee; 1993-1997 Clinical Affairs Committee 2000-2003 Research Award Committee 2005 Chair, Cancer Biometrics Society of University Surgeons Surgical Biology Club World Association of Hepato-Pancreatico-Biliary Surgery 4
  5. 5. EDITORIAL BOARDS 1988 European Cytokine Journal 1990 J. Immunotherapy (Formerly J. Biological Response Modifiers, Assoc. Editor) 1990-1995 J. Immunology 1990-1994 Contemporary Oncology 1991 General Surgery & Laparoscopy News (Surgical Oncology) 1991 Melanoma Research 1993 Therapeutic Immunology 1993 Cancer Research, Therapy and Control 1994 Cancer Gene Therapy, Associate Editor 1995 Clinical Cancer Research (Associated with AACR) 1995 Natural Immunity 1995 The Cancer Journal, Associate Editor 1995 Gene Therapy (Nature) 1995 Cytokines and Molecular Therapy 1996 Human Gene Therapy 1997 Cancer Therapeutics 1999–2001 Clinical Immunology 2000 Current Opinion in Investigational Drugs, Gene Therapy/Oncology Section Editor 2003 Journal Immunotherapy, Associate Editor 2003 The Oncologist, Associate Editor for Immunotherapy and Antibodies 2004 Molecular Cancer Therapeutics, AACR 2005 Translational Research 5
  6. 6. ACTIVITIES 1983-1990 Hospital Infection Control Committee, NIH 1984 Member, Source Evaluation Group RFP NCI CM 37613-64; "Phase I/II Clinical Evaluation of BRMs for the Treatment of Cancer” 1985-1990 Project Officer, Cell Sorting Operation, Surgery Branch, NCI 1985 FDA License Committee, Interferon Licensure in Melanoma 1985 Member, Source Evaluation Group RFP:NCI. CM 37613-64; MAO 4,5:Phase I Clinical Trial of Cytotoxic Activated Lymphocytes/IL-2 1985 Amer. Coll. Surgeons Rep.; CDC Task Force: Recom-mendations for Preventing Transmission of Infection with Human T-Lympho-trophic VirusType III- Lymphadenopathy-associated Virus During Normal Procedures. 1985-1987 Coordinator, NIH Melanoma Working Group 1985-1987 Review Board, United Cancer Council, Inc., Rochester, NY 1987 Chairperson, Minisymposium on In Vivo Effects of Cytokines; FASEB, Washington, D.C. 4/1/87 1987 Representative, NCI Melanoma Clinical Strategy Group 1988-1990 Surgery Br. Rep., NCI Investigational Review Board 1989 Cochairperson, Minisymposium on T-cells and the Treatment of Cancer, AACR, San Francisco, CA; 5/25/89 1990 Ad Hoc Reviewer, Experimental Immunology Study Section, NIH 1990 Cancer Group, National Disease Research Interchange; 9/17/90 1990 Surgical Forum Moderator (Tumor Immunology), American College of Surgeons; San Francisco, CA; 10/8/90. 1990 Chairman, Special Study Section, Experimental Immunology, NIH 1990 Cancer Vaccine Workshop, NCI; Bethesda, MD; 10/29/90 1991 Planning Committee, NIH Consensus Development Conference on the Diagnosis and Treatment of Early Melanoma 1991 Participant, NIH Training Grant, University of Pittsburgh, "Molecular 6
  7. 7. Mechanisms and Therapy of Childhood Diseases" 1991 Chairperson, Minisymposium on Antitumor Effectors; FASEB,Washington DC; 4/22/91 1991 Society of Surgical Oncology/Program Committee/Research and Government Relations Committee 1992 - 1995 American Society of Clinical Oncology Young Investigator Award, Clinical Development Award Committee 1992 Search Committee, Chair UPMC Director Radiation Oncology 1992-1995 External Advisory Committee, "Immunity to Lung Tumors and Melanoma by Gene Transfer to Tumors and Tumor-specific CTL", University of Miami Cancer Institute, PI, Eckhard R. Podack, MD 1993 What's New in Surgical Oncology, Amer. College of Surgeons 1993 Search Committee, Breast Cancer Center Director, UPMC/PCI 1993-2000 Mellon/Dickson Prize Committee; University of Pittsburgh School of Medicine; Chair 1997-2000 1994 Search Committee, NSABP Chairman, UPMC 1994 External Advisory Committee, "Gene Therapy for Solid Tumors", Baylor College of Medicine, PI, Savio Woo, Ph.D. 1994-Present Executive Council, Society for Biologic Therapy; Vice President (1996); President 1998-2000; Immediate Past President 2000-2002. 1995-1996 UICC/American Cancer Society Fellowship Committee 1996 External Advisory Committee, "Gene Therapy of Cancer", Memorial Sloan- Kettering Cancer Institute, PI, Lucio Luzzatto, MD 1997 Site Visit Committee, National Institutes of Health, National Cancer Institute; Frederick Cancer Research Center, Branch Chief, John Ortaldo. 1997 UPMC/Health Sciences International Committee 1997 Site Visit Committee, National Institutes of Health, National Cancer Institute; Section of Tumor Immunology, Branch Chief, Jeffrey Schlom. 1997 Site Visit Committee, National Institutes of Health, National Cancer Institute; 1 RO1 CA76489-01 Dr. Donald L. Morton Polyvalent Vaccine: Phase III Trial in 7
  8. 8. Stage IV Melanoma; John Wayne Cancer Institute; August 5, 1997. 1997-2000 Cardinal Bernardin Cancer Center External Advisory Council (Loyola University Medical Center) 1997-2003 Melanoma Research Foundation, Board of Trustees 1998 TK Immunotherapy Expert Panel; Rhone Polenc Rorer 1998 Search Committee, Chief of Urology University of Pittsburgh 1998-2001 Ohio State University Scientific Advisory Committee; Arthur G. James Cancer hospital and Research Institute 1998 Biosafety Committee, Mercy Hospital (Adenoviral p53 Gene Therapy) 1998 Clinical Trials Steering Committee; University of Pittsburgh Medical Center 1998 Search Committee, Chief of Medicine University of Pittsburgh 1998 Standing Committee for Faculty Recognition and Research Awards, U. Pittsburgh 1997-2001 Peer Review Committee on Cliical Research, Cancer Control and Epidemiology; American Cancer Society 1999 Co-Director, Gene Therapy Program, SmithKline Beecham 1999 Co-Director, Protein Agent Strategic Initiative, SmithKline Beecham 1999-2000 Co-chair, Cancer Gene Therapy Committee of the American Society of Gene Therapy (ASGT) 2000 Sponsored, developed, and ran SB Symposium on "Tissue Repair and Wound Healing, Therapeutic Opportunities" Upper Providence, March 2-3, 2000. 2000 Grand Rounds, University of Pennsylvania Cancer Center; In Vivo Veritas – Lessons for Immunotherapy of Cancer; April 20, 2000. 2001 New York Academy of Sciences; Codirector; Symposium on Use of Viral Vectors for Target Validation with Tom Kost; December 4, 2001 2001 Study Section; Chemoprevention of tobacco-related cancers in former smokers: preclinical studies; RFA CA-02-008; December 6, 2001; Nov 4, 2002. 2002 American Society of Clinical Oncology Discussant; Annual Meeting, Orlando; Enhancing the antitumor effects of IL-2. 8
  9. 9. 2002 Amer. Association for Gene Therapy; Meet the Professor Session – Immunology 2002 James Ewing Young Investigator Award for Clinical Research; Society of Surgical Oncology; Selection Committee 2002 External Advisor/ PI Savio Woo Mt. Sinai School of Medicine; Gene Therapy of Colorectal Cancer 2002 Scientific Advisory Board, Association for Cancer Gene Therapy 2002 Guest Editor with Brigitte Autran, Hervé Fridman, and Bruce Walker. Special Issue – Vaccine [Volume 20 Supplement 4 19 December 2002]: Therapeutic Vaccines Against HIV and Cancers 23-26 June 2002, Les Pensières, Veyrier-du- Lac, Annecy, France; Organized by the Merieux Foundation with the support of Aventis Pasteur and Mérial 2003 External Advisor/PI Thomas Kupper Harvard Medical School; NCI funded Melanoma SPORE 2003 Coorganizer with Laurence Zitvogel: FOCiS-iSBTc Satellite Symposium on Cellular Immunology and the Immunotherapy of Cancer V Thursday Afternoon May 15th, 2003 2003 Liver Proteomics Meeting, NIDDK; Chaired by Laura Beretta 2003 Esternal Advisor/PI Hans-Georg Klingermann Rush-Presbyterian St. Luke’s Medical Center; Immunotherapy for Bone Marrow Grafting 2003 Coorganizer 1st International Society of Biological Therapy Workshop on Proteomics, Genomics and High Content Cellular Screening in Patients with Cancer with Ena Wang, MD, PhD Dept. of Transfusion Medicine, National Institutes of Health; Nabil Hanna, PhD, Chief Scientific Officer, IDEC Pharmaceuticals Masur Auditorium, National Institutes of Health; October 30, 2003 2003 External Advisor/Consultant; Immune Tolerance Network 2004 Grand Rounds, Roswell Park Cancer Institute; January 21, 2004 2004 Symp. VIII Moderator, Biology and Therapeutic Application of DCs in Chronic Inflammation; 6th Congress - Trauma, Shock, Inflammation and Sepsis; March 3, 2004 2004 NCI Clinical Oncology Study Section June, October [Ad hoc] 2004 AACR/ASCO Vail Clinical Protocol Development Faculty 9
  10. 10. 2004-2006 Scientific Programs Committee ASCO 2004 NCI Study Section, Strategic Partnersing to Evaluate Cancer Signatures [RFA- CA-04-015]; November 18-19, 2004 2005 ASCO Member of the Program Committee; Developmental Therapeutics: Immunotherapy Track 2005 Mentor; The Jack Kent Cooke Foundation and the American Psychological Association's Center for Gifted Education Policy; APEX Program 2005 Immunology Series [Lectures] in the BIOE 2521 Molecular Cell Biology and Biophysics II course led by Partha Roy [Bioengineering] Honors 1971-1974 Honors Program in Medical Education 1982 Robert H. White Award for Excellence in Teaching, Univ. of Rochester 1986 Edith Hamilton Cancer Lecturer, Genesee Hospital/Wasyl Pluta Cancer Center, Rochester, NY 1987 Special Achievement Award; Dept. Health & Human Services, NIH. 1988 4th Vender Lecturer, Northwestern University; Evanston, Illinois 1989 Visiting Professor, Dept. of Surgery, Duke University; Durham, NC 1990 Coorganizer Keystone Symposium on Cellular Immunity and the Immunotherapy of Cancer, Park City, UT 1990 Virginia Mason Res. Center Distinquished Lecturer, Seattle WA 1990 14th Annual Lecturer, Internal Medicine Group; New Orleans, LA. 1991 Annual John Palmer Lecturer, Univ. of Toronto; Toronto, Ontario 1991 Tenth Hinshaw Lecturer, Univ. of Rochester, Rochester, New York 1992 Coorg. Keystone Symp.on Melanoma and Biology of the Neural Crest, Taos, NM 1992 Coorganizer, Roundtable Roussel-UCLAF on Cytokines and Cancer, Versailles, France, 10/7-9/92 1992 Chairman, Cancer Care Committee, Pittsburgh Cancer Institute 10
  11. 11. 1993 Organizer, Symposium Molecules to Medicine, 2nd Inter. Congress on Biol. Response Modifiers; San Diego, CA; 1/29/93 1993 Coorganizer Keystone Symposium on Cellular Immunity and the Immunotherapy of Cancer II, Taos, NM; 3/17-24/93. 1993 Cochairman, Symp.Tumor Immunology, Denver CO; AAI/CIS 5/29/93. 1993 Visiting Professor of Surgical Oncology; Academia Sinica/Veteran's General Hospital; Taipei, Taiwan; 6/27/93-7/15/93. 1994 NIH Committee (Mail Ballot-Scientific Meetings and Conferences). 1994 Sommer Memorial Lecture, Portland, Oregon; April 21-22, 1994. 1994 Site Visit Chairman, NIH PO1-CA64254-01. Brain Tumor Gene Therapy; June 14-16, 1994 1994 Plenary Speaker, Centennial Celebration of the Royal Victoria Hospital; June 9, 1994 1995 EJ Tabah Lectureship, McGill University; March 13-15, 1995. 1995 First Peter Finke Lecturer; Memorial Sloan Kettering; Sept. 15, 1995. 1995 Coorganizer, New York Academy of Sciences Symposium: Interleukin 12; An important regulatory cytokine. November 9-12, 1995; NYC. 1996 Reverse Site Visit Committee Stanford University Medical Center General Clinical Research Center; July 30, 1996; Rockville, MD. 1996 Site Visit Committee; Laboratory of Experimental Immunology; Div. of Basic Sciences; NCI; Frederick, MD; November 5, 1996. 1996 McCutcheon Lectureship, University of Toronto; November 8, 1996. 1997 Distinguished Lecturer, Robert Wood Johnson UMDNJ; January 15, 1997. 1997 Coorganizer, Keystone Symposium on Cellular Immunology and the Immunotherapy of Cancer; Copper Mountain, February 1-7, 1997. 1997 Distinguished Lecturer, Westmoreland Hospital; Greensberg, PA 1997 University of Pittsburgh Cancer Institute Scientific Leadership Award 1998 Coorganizer, 5th International DC Meeting; Pittsburgh; September 24-28, 1998. 11
  12. 12. 1998 Coorganizer, 13th Society for Biological Therapy Meeting, Pittsburgh; October 21-21, 1998. 1998-2001 Visiting Professor of Oncology, Shanghai Medical University (SMU) 2000 Co-Organizer, 4th Keystone Symposium on Cellular Immunology and the Immunotherapy of Cancer; Santa Fe, NM January 21-27, 2000 2000 Keynote Speaker, American Association of Cancer Research Special Meeting on Melanoma; The Woodlands, Texas May 3-7, 2000. 2000 Coorganizer, American Association of Cancer Research Special Meeting on Cytokines; Vail Colorado; September 20-23, 2000. 2000 Visiting Professor; Wistar Instititute; Philadelphia, PA; April 28, 2000. 2001 Plenary Lecture, Japanese Surgical Society, April 2001 2002 Danny Hill Tumor Immunology Lectureship, University of Western Australia, Perth, Australia 2002 Surgical Grand Rounds, Columbia University August 29, 2002. 2002 Surgical Grand Rounds, Montefiore Hospital/Albert Einstein University; October 21, 2002. 2003 Surgical Forum; Plenary Speaker Society Surgical Oncology; March 10, 2002. Los Angeles, CA 2003 Keynote Speaker Carolyn Frye-Halloran Symposium and Grand Rounds Combined Neurology, Neurosurgery, Psychiatry Grand Rounds; Massachussetts General Hospital, September 04, 2003; Boston, MA. 2003 Surgical Grand Rounds, Northwestern University/Evanston Hospital; October 10, 2003 2004 Organizer Biology and Therapeutic Application of DCs In Chronic Inflammation 6th World Congress on Trauma, Shock, Inflammation and Sepsis – Patho- physiology, Immune Consequences and Therapy March 2nd-6th, 2004, Munich, Germany 2004 Dermatology Grand Rounds, Johns Hopkins University; June 16, 2004. 2004 Member Ad Hoc Scientific Counselors, Clinical Center NIH [Review Dept Transfusion Medicine] 12
  13. 13. 2004 Ad Hoc Member, Clinical Oncology Study Section, NCI 13
  14. 14. REGULATORY EXPERIENCE WITH FDA/RAC/IRBS 1979 TCGF Expanded Lymphocytes for Cancer [Clinical Center, NIH] 111 1981 In oxine labeled leucocytes; personnel IND in setting of transplantation 1983 Jurkat-derived IL-2; Personal IND and clinical protocol with Dupont 1985 Recombinant IL-2; Intraperitoneal administration; Cetus – IND holder; NCI protocol 1987 Recombinant IL-4; IND with FDA to MTL alone/combination with IL-2; Sterling Pharmaceuticals 1989 Recombinant IL-2 and Immunoglobulins; IND with FDA to MTL; with Cetus Presentation to RAC on Neo-transfected TILs for cancer therapy 1991 IND IL-2 and activated natural killer cells for regional infusion 1992 IL-4 Gene Therapy; RAC/FDA IND/IRB submissions 1995 IL-12 Gene Therapy; RAC/FDA IND/IRB submissions Presentation to FDA on rIL-2 for Chiron for licensing in melanoma 1998 DC based therapy of melanoma; FDA IND/IRB submissions 2001 Pre-IND and IND meetings for GlaxoSmithKline on IL-18 protein therapy 2003 Pre-IND meetings for iNOS gene therapy for vascularized shunts 2003 Integrating NK and DC in the therapy of cancer; protocol development; IND preparation 2004 Protocol development, regional therapy of melanoma 14
  15. 15. Research Grants 9/92-10/96 NIH 1UO1 CA 58272-01 "Locoregional ALT with autologous IL-2, activated NK cells", Principal Investigator, $800,000. 9/92-10/94 NIH 1PO1 CA59371-01 "Gene Therapy of Cancer - Immunological Approaches", Principal Investigator, $750,000. 9/92-8/94 NIH 1ROA CA56088-01A1 "Specific T-cell Recognition of Human Melanoma", Principal Investigator, $100,000. 8/93-9/97 NIH 1RO1 CA 57804-01A1 "Identification of Class I Presented Peptides", Co- Principal Investigator, $466,808. 10/91-10/93 VA RAG "Breaking Tolerance with Cytokine Based Cancer Immunotherapy", Coinvestigator, $68,000. 1995-1998 Schering Plough Research Institute. “Gene Therapy with IL-4, IL-10, vIL-10, and interferon alpha”, Principal Investigator, $1,000,000. 4/96-5/01 NIH (1RO1CA63350-01) "Dendritic Cell Based Therapies Designed for Murine Tumors", Co-Principal Investigator, $1,060,434. 2/94-3/99 NIH (NCI-CM-47001-64) "Clinical Trials of Biologic Response Modifiers", Principal Investigator, $2,874,341. 4/94-3/96 NIH (NCI-1R21CA69106-01) "Emulsion Based Therapy of Cancer", Coinvestigator, $96,000. 7/95-6/99 NIH (NCI-1P01 CA 68067-01) "Cytokine Gene Therapy of Cancer", Principal Investigator, $4,261,226. 11/95 NIH (1 R13 CA68006-01) "Interleukin 12: Immunology of a Regulatory Cytokine",Principal Investigator, $47,900. 10/96 NIH 1PO1 DE12321. “Vaccine Development for Head and Neck Cancer,” Principal Investigator, Project 3. PI Dr. Theresa Whiteside, $2,500,000. 8/96-6/00 NIH NCI 1UO1CA74329-01. “Clinical Trials of Biological Response Modifiers. Principal Investigator, $550.951. 02/97 NIH 1R13CA73576-01. “Conference on Cellular Immunology of Cancer,” Principal Investigator, $50,000. 04/97-03/02 NIH NCI-1RO1CA73816-01.”Dendritic cells elicit effective antitumor responses,” Coinvestigator (PI, Walter J. Storkus), $1,429,008. 15
  16. 16. 7/97-6/02 NIH NCI 1PO1DE12321-01. “Vaccine Development for Oral Carcinoma.” Principal Investigator, Project 1. PI Dr. Theresa Whiteside, $2,600,000 11/97 NIH NCI-1PO1CA73743-01. "DC Biology and Therapy", CoPI, $9,978,000. 11/97 NCI-1K12CA76906-01. “Biologic Therapy Research Career Development Program.” Co Principal Investigator, $1,660,371. 1998 Argonex, Inc. “Identification of T-cell targets in colorectal and ovarian carcinoma.” Principal Investigator, $137,952. 01/98-12/02 NIH NCI 1PO1CA7374301A1 “Dendritic Cell Biology and Therapy. Principal Investigator, $9,021,156. 09/98-09/02 PAR-97-080 "Novel HIV Therapies: Integrated Preclinical/Clinical Program"; Project 4: Dendritic Cell Therapy for HIV: Role of Cytokines on Enhanced T-cell Function"; Total $1,380,101; PI Michael Lotze, CoPI Cara Wilson. 06/01/99-05/30/04 “Research Training in AIDS, STDs and Emerging Infections;” PI David Tweardy; Total $747,573; Mentor/Training Faculty 03/00-02/05 NIH NCI 1RO1CA82016-01A29 “Melanoma Associated T & DC Dysfunction and Death. Principal Investigator, $1,676,406. 04/00-03/05 NIH NCI 2PO1CA68067 Cytokine Gene Therapy of Cancer, CoPI, $9,861.090 02/01/04 Submitted to the NCI; “Integrating NK and DC into Cancer Care”; 3 projects; 3 cores; Principal Investigator, CoPI, Ronald Herberman; $13,811,383. 3/1/04-2/29/08 1 RO1 CA 100415-01 $1, 189,733; Development of a tumor selective replicating vaccinia; David L. Bartlett, PI; MTL, coinvestigator 10% 04/01/04 RFA-RM-04-005 National Technology Centers for Networks and Pathways Fluorescent Probes and Imaging for Pathways; Alan S. Waggoner, PI; National Institutes of Health; $14,435,640; Michael T. Lotze Co-PI; 30% 06/01/04 1PO1 CA 113698-01; Regional Therapy of Cancer; Submitted to the NCI; “3 projects; 3 cores; Principal Investigator, CoPI, David Bartlett; $10M EDRN 04/01/04 Project 2: Luminex Multianalyte and SELDI-TOF-MS Serum Proteomic Profiling of Pancreatic Cancer; Herbert J. Zeh, PI; Michael T. Lotze, 10% 07/01/04 1RO1CA106534-01 Detection of Molecular Markers of Melanoma and Response to Interferon Therapy; CoPI, John M Kirkwood, Michael T Lotze, William L Bigbee; 10%; $1,850,000 09/01/04 Tolerogenic DC Therapy for Thoracic Organ Transplant. PI Kenneth R. McCurry; 16
  17. 17. Coinvestigator, Michael Lotze; 5% + technical support 50%; $1,843,745 10/01/04 NIDDK; Chronic Inflammation of the Liver. PI Anthony J. Demetris; Co-PI, Michael T. Lotze; 30%; $5,000,000 06/01/05 NIDDK; Gut Inflammation. PI Michael T. Lotze; Co-PI, Mitchell Fink; 30%; $5,000,000 17
  18. 18. PATENTS Storkus Walter, Michael T. Lotze. Rapid Isolation of T-cells Epitopes from viable cells by mild acid elusion. (November 23, 1999; 5,989,565) Baar Joseph, Michael T. Lotze. Interferon/gamma inducible cytokine expression plasmids. Tahara Hideaki, Michael T. Lotze. In situ injection of antigen-presenting cells with genetically enhanced cytokine expression. U Pittsburgh Reference Number 181; 09/395,836. Filed September 14, 1999; issued August 6, 2002. Thomson Angus, Lu Lina, Michael T. Lotze - “Genetic engineering of dendritic cells for immunosuppressive therapy” Disclosure Tahara Hideaki, Michael T. Lotze. Modified interferon gamma inducing factor (IGIF/IL-18) sequence which can be secreted as an active form IL-18 protein from mammalian cells. Angus W. Thomson, Lina Lu, Michael T. Lotze. Genetically Modified Antigen Presenting Cells for the Induction of Immunointolerance. Siamak Agha-Mohammadi, Michael T. Lotze. PCT/US01/31138. High Efficiency-Regulatable Expression System FILMS 1986 Demonstration of intraoperative ultrasound imaging, CO2 laser surgery and CUSA ultrasonic dissection for a right hepatic lobectomy for hepatoma; Spectacular Problems in Surgery, ACS 1992 Immunotherapy Video Handbook, ProleukinR 1995 Resection of a Giant Lipoma; ACS Cine Forum, New Orleans, October 22-27, 1995. 18
  19. 19. BOOKS 1990 Cellular Immunity and the Immunotherapy of Cancer, Ed. Lotze MT, Finn OJ, Wiley-Liss; New York, 1990. 1994 Current Cancer Therapy, Ed. Kirkwood JM, Lotze MT, and Yasko J; 1998 Current 1996 Science, Philadelphia, 1994; 2nd Edition 1996; 3rd Edition 1998; 4th Edition 2001. 1998 2001 1996 Interleukin 12: Cellular and Molecular Immunology of an Important Regulatory Cytokine. Ed. Michael T. Lotze, New York Academy of Sciences, NY. 1997 Regional Therapy of Advanced Cancer, Ed. Lotze MT, Rubin JT; JB Lippincott, Philadelphia, 1997. 1999 Dendritic Cells: Biology and Clinical Applications; Ed. Michael T. Lotze, Angus W. 2001 Thomson; Academic Press; London; 2nd Edition 2001 2006 3rd Edition 2002 Tumor Immunology: Molecularly Defined Antigens and Clinical Applications. Ed. Giorgio Parmiani and Michael T. Lotze; Taylor and Francis, London; 2002. 2003 Cytokine Handbook, 4th Edition. Ed. Angus W. Thomson, Michael T. Lotze; Academic Press, London; 2003. 2005 Measuring Immunity, 1st Edition. Ed. Michael T. Lotze, Angus W. Thomson; Academic Press, London. 2006 Natural Killer Cells, 1st Edition. Ed. Michael T. Lotze, Angus W. Thomson; Academic Press, London. 19
  20. 20. SCIENTIFIC ADVISORY BOARDS 1990-1994 Cellco, Inc. Rockville, MD; Hollow-fiber growth of cells 1995-1998 Canji, Inc; Subsidiary of Schering Plough, Inc. Gene Therapy [p53, RB, cytokines] 2002-current Immunodesigned Molecules, Inc. Parisian company involved with cell/DC therapy 2002-current Tissue Informatics, Inc. Pittsburgh company involved with machine vision tissues 2002-current CureTech, Inc. Tel Aviv company involved with developing antibody therapies 2002 BioMeasure; Boston; consultant on therapeutic vaccines for cancer 2003 MediGene, Munich; consultant on therapeutic vaccines for cancer 2003 Coley Pharmaceuticals, Wellesley; consultant on biomarkers/surrogates for cancer 2003 Allergan Pharmaceuticals, Irvine, CA; consultant on immunogeneicity of recombinant proteins 2003-Present Medarex Pharmaceuticals, Bloomsfield NJ; consultant on clinical trials with MDX-010 2004 ZelleRx, Chicago, IL; consultant on therapeutic use of NK cells; on Scientific Advisory Board 2004 Becton Dickinson; consultant on antibody development and application in flow and imaging cytometry 2004 Chiron; consultant on development of combination therapies with IL-2 2005 Sanofi-Aventis; consultant on cancer vaccines 20
  21. 21. MARATHONS 1985 Marine Corps 1990 Pittsburgh 1993 Pittsburgh 1998 Pittsburgh, Bordeaux [Marathon des Chateaux du Medoc], Marine Corps 1999 Pittsburgh, Cincinnati Flying Pig, Helsinki, San Diego Rock and Roll, New York 2000 Philadelphia, Boulder Outback, Quebec City, Marine Corps, Vancouver, Jacksonville 2001 Philadelphia, Pittsburgh, London, Seattle 2002 Paris, Pittsburgh, Buffalo, San Francisco, Bordeaux [Marathon des Chateaux du Medoc], New York [1/2], Seattle 2003 Chicago, Marine Corps 2004 Phoenix Rock and Roll, IKEA Half, New York Half, Tucson Half 2005 Nashville [planned] 21
  22. 22. BIBLIOGRAPHY 1. Lotze, M.T., Strausser, J.L., Rosenberg, S.A. In vitro growth of cytotoxic human lymphocytes. II. Use of T cell growth factor (TCGF) to clone human T cells. J. Immunol.124:2972-2978, l980. 2. Dubois, M., Lotze, M.T., Diamond, W.J., Kim, Y.O., Flye, W.M., Macnamara, T.E. Pulmonary shunting during leukagglutinin induced noncardiac pulmonary edema. JAMA 244:2l86-9, l980. 3. Lotze, M.T., Lines, B.T., Strausser, J.L., Rosenberg, S.A. Tumor lysis by human T lymphocytes in long term culture and their distribution in vivo: Implications for immunotherapy. Surg. Forum 31:404-406, l980. 4. Lotze, M.T., Lines, B.T., Mathisen, D.J., Rosenberg, S.A.: The in vivo distribution of cultured autologous human and murine lymphoid cells grown in T cell growth factor (TCGF): Implications for the adoptive immunotherapy of tumors. J. Immunol. l25:2972-2978, l980. 5. Bias, W.B., Hsu, S., Pollard, M.K., Harvey, J., Lotze, M.T., Arnett, F.C., Stevens, M.B.: HLA- DR characterization of a Chippewa Indian subpopulation with high prevalence of rheumatoid arthritis. Human Immunol. 2:l55-l63, l98l. 6. Lotze, M.T., Rosenberg, S.A.: In vitro growth of cytotoxic human lymphocytes. III. The preparation of lectin free T cell growth factor (TCGF) and an analysis of its activity. J. Immunol. l26:2215-2220, l98l. 7. Lotze, M.T., Grimm, E.A., Mazumder, A., Strausser, J.L., Rosenberg, S.A.: Lysis of fresh and cultured autologous tumor by lymphocytes cultured in T cell growth factor (TCGF). Cancer Res. 4l:4420-4425, l98l. 8. Lotze, M.T., Duncan, M.A., Gerber, L.H., Woltering, E.A., Rosenberg, S.A.: Early versus delayed motion following axillary dissection: A randomized, prospective study. Ann. Surg. l93: 288-295, l98l. 9. Harvey, J., Lotze, M.T., Stevens, M.B.: Rheumatoid arthritis in a Chippewa band. I. Pilot screening study of disease prevalence. Arth. Rheum., 24: 7l7-72l, l981. 10. Strausser, J.L., Mazumder, A., Grimm, E.A., Lotze, M.T., Rosenberg, S.A.: Lysis of human solid tumors by autologous cells sensitized in vitro to alloantigens. J. Immunol. l27: 266-27l, l98l. 11. Rosenberg, S.A., Grimm, E.A., Lotze, M.T., Mazumder, A.: The growth of human lymphocytes in T-cell growth factor: Potential applications to tumor immunotherapy. Lymphokines. Mizel, S.F. (ed), Academic Press: New York, 1982. l2. Rosenberg, S.A., Eberlein, T.J., Grimm, E.A., Lotze, M.T., Mazumder, A., Rosenstein, M.: Development of long-term cell lines and lymphoid clones reactive against murine and human tumors: A new approach to the adoptive immunotherapy of cancer. Surgery 92:328-335, 1982. 22
  23. 23. l3. Harvey, J., Lotze, M.T., Bias, W.B., Hsu, S., Arnett, F.C., Stevens, M.B.: Rheumatoid arthritis in a Chippewa band. II. Field study with clinical, serologic and HLA-D correlations. J. Rheumatology. l0:28-32, l983. l4. Lotze, M.T., Marquis, D.M., Carey, A.S., Byer, B.J., Hoy, W.E., May, A.G.: Two new assays for the early detection of transplant rejection, Interleukin-2 response and PHA-augmented NK activity. Transplantation Proceedings l5:l796-l799, l983. l5. Duncan, M.A., Lotze, M.T., Gerber, L., Rosenberg, S.A.: Incidence and recovery of serratus anterior palsy following axillary dissection. J Amer. Phys. Ther. Assn. 63:l243-l247, l983. 16. Ouriel, K., Lotze, M.T., Hinshaw, J.R.: Prognostic factors of carcinoma of the male breast. Surg. Gynec. Obst. 159:373-376, 1984. l7. Donohue, J.H., Rosenstein, M., Chang, A.E., Lotze, M.T., Robb, R.J., Rosenberg, S.A.: The systemic administration of purified Interleukin-2 enhances the ability of sensitized murine lymphocyte lines to cure a disseminated syngeneic lymphoma. J. Immunol. 132:2123-2128, 1984. 18. Grimm, E.A., Vose, B.M., Chu, E.W., Wilson, D.J., Lotze, M.T., Rayner, A.A., Rosenberg, S.A.: The human mixed lymphocyte tumor cell interaction test I. Positive autologous lymphocyte proliferative responses can be stimulated by tumor cells as well as by cells from normal tissues. Cancer Immunol. & Immunotherapy 17:83-89, 1984. l9. Donohue, J.H., Lotze, M.T., Robb, R.J., Rosenstein, M., Braziel, R.M., Jaffe, E.S., Rosenberg, S.A.: In vivo administration of purified Jurkat derived Interleukin-2 in mice. Cancer Research 44:1380-1386, 1984. 20. Rosenberg SA, Rosenstein M, Grimm E, Lotze, M, Mazumder A. The use of lymphoid cells expanded in IL-2 for the adoptive immunotherapy of murine and human tumors.In Thymic Hormones and Lymphokines. Goldstein A.L.; Plenum Pub. Co., NY, 1984; pgs. 191-207. 21. Chang AE, Lotze MT, Ames RS, Rosenberg SA. A large scale method for the purification of Interleukin-2 secreted by the murine EL-4 thymoma. J. Immunopharmacology 7:17-31, 1985. 22. Lotze, M.T., Robb, R.J., Frana, L.W., Seipp, C.A., Sharrow, S.O., Gelman, E.T., Longo, D.L., Rosenberg, S.A.: Clinical studies with purified human IL-2 in patients with the acquired immunodeficiency syndrome and cancer in UCLA Symposium:AIDS; Alan R. Liss, Inc. Press, NY, 1984; J. Groopman, M. Gottlieb. 23. Lotze MT, Rosenberg S. In vivo use of cytokines.Clin. Immun. Newsletter, 5:116-120, 1984. 24. Lotze, M.T., Robb, R.J., Sharrow, S.O., Frana, L.W., Rosenberg, S.A.: Systemic administration of interleukin-2 in man. J. Biol. Resp. Mod. 1984, 3:475-482, 1984. 25. Lotze, M.T., Rosenberg, S.A.: Immunologic changes in patients with cancer given interleukin-2 (IL-2) in a phase I trial. Surg. Forum, 1984, 35:407-408, 1984. 23
  24. 24. 26. Rayner, A.A., Grimm, E.A., Lotze, M.T., Rosenberg, S.A.: Demonstration of shared recognition and lysis of autologous and allogeneic fresh human tumors by cloned lymphokine activated killer (LAK) cells. Surg. Forum, 1984, 35: 415-417. 27. Lotze, M.T., Sugarbaker, P.H.: Femoral artery based myocutaneous flap for hemipelvectomy closure; Amputation following failed limb-sparing surgery and radiation therapy. Am. J. Surg. 150: 625-630, 1985. 28. Rayner, AA, Grimm, EA, Lotze, MT, Wilson, DJ, Rosenberg, SA: Lymphokine-activated killer (LAK) cell phenomenon:IV. Lysis by LAK cell clones of fresh human tumors from autologous and multiple allogeneic tumors. JNCI 75:67-75, 1985. 29. Rayner, A.A., Grimm, E.A., Lotze, M.T., Chu, E.W., Rosenberg, S.A.: Lymphokine activated killer (LAK) cells. Analysis of factors relevant to the immunotherapy of human cancer. Cancer 55:1327-1333, 1985. 30. Lotze MT, Frana LW, Sharrow SO, Robb RJ, Rosenberg SA. In vivo administration of purified human IL-2 I.Half life and immunologic effects of the Jurkat cell line derived Interleukin 2. J. Immunol. 134:157-166, 1985. 31. Lotze, M.T., Rosenberg, S.A.: Treatment of tumor patients with purified human interleukin-2. (In) Cellular and Molecular Biology of Lymphokines. Academic Press, 1985, pp. 711-721. 32. Lotze, M.T.: Current and future research directions in management of hepatic cancer in Hepatoma, ed. H. Wanebo, Marcel Decker, NY, 1986, pp. 501-534. 33. Lotze, M.T., Rayner, A.A., Grimm, E.A.: Problems with the isolation of lymphoid clones with reactivity to human tumors. Behring Institute Research Communications., 1985, 77:105-14. 34. Longo, D.L., Steis, R.G. , Lane, H.C., Lotze, M.T., Rosenberg, S.A., Preble, O., Masur, H., Rook, A.H., Fauci, A.S., Jacob, J., Gelmann, E.P.: Malignancies in the AIDS patient: Natural history, treatment strategies, and preliminary results. Ann. N.Y. Acad Science, 837:421-430, 1984. 35. Lotze, M.T., Rosenberg, S.A.: Treatment of immunologic disorders in AIDS patients. In Devita VT, Hellman S, Rosenberg SA (eds): Acquired Immune Deficiency Syndrome. Philadelphia, J.B. Lippincott, 1985: pp. 235-264. 36. Lotze, M.T., Matory, Y.L., Ettinghausen, S.E., Rayner, A.A., Sharrow, S.O., Seipp, C.A.Y., Custer, M.C., Rosenberg, S.A.: In vivo administration of purified human interleukin-2. II. Half life, immunologic effects and expansion of peripheral lymphoid cells in vivo with recombinant interleukin-2. J. Immunol. 135:2865-2875, 1985. 37. Lotze, M.T., Matory, Y.L., Rayner, A.A., Ettinghausen, S.E., Seipp, C.A., Rosenberg, S.A.: Toxicity of interleukin-2 in patients with cancer. Cancer. 58:2764-2772. 1986. 38. Skibber, J.M., Lotze, M.T., Garra, B., Fauci, A.: Successful management of hepatic abscesses by percutaneous catheter drainage in chronic granulomatous disease. Surgery. 99:626-630, 1986. 24
  25. 25. 39. Lotze, M.T.: Stemming Cancer in the 80's. AIDS: A surgeon's responsibility. Bulletin of the American College of Surgeons. 70:6-12, 1985. 40. Edington, H., Lotze, M.T.: V-Y closure in abdominal wall stoma reduction. Surgery, Gynecology, and Obstetrics. 164:381-382, 1987. 41. Lotze, M.T., Custer, M.C., Sharrow, S.O., Rubin, L.A., Nelson, D.L., Rosenberg, S.A.: In vivo administration of purified human interleukin-2. III. Development of Tac positive cells and circulating soluble interleukin-2 receptors following interleukin-2 administration to humans. Cancer Res. 47:2188-2195, 1987. 42. Rosenberg, S.A., Lotze, M.T.: Cancer immunotherapy using interleukin-2 and interleukin-2- activated lymphocytes. Ann. Rev. Immunol. 4:681-709, 1986. 43. Rosenberg, S.A., Lotze, M.T., Muul, L.M., Leitman, S., Chang, A.E., Ettinghausen, S.E., Matory, Y.L., Skibber, J.M., Shiloni, E., Vetto, J.T., Seipp, C.A., Simpson, C., Reichert, C.M.: Observations on the systemic administration of autologous lymphokine activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. NEJM. 313:1485-1492, 1985. 44. Perez, P., Titus, J.A., Lotze, M.T., Cuttita, F., Longo, D.L., Groves, E.S., Rabin, H., Durda, P.J., Segal,D.M.: Specific lysis of human tumor cells by T cells coated with anti-T3 crosslinked to anti-tumor antibody. J. Immunol. l37:2069-2072, l986. 45. Rosenberg, S.A., Lotze, M.T., Muul, L.M., Leitman, S., Chang, A.E., Vetto, J.T., Seipp, C.A., Simpson, C.A.: A new approach to the therapy of cancer based on the systemic administration of autologous lymphokine activated killer cells and recombinant interleukin-2. Surgery l00:26l-71, l986. 46. Lotze, M.T., Chang, A.E., Seipp, C.A., Simpson, C., Vetto, J.T., Rosenberg, S.A.: High dose recombinant interleukin-2 in the treatment of patients with disseminated cancer: Responses, treatment related morbidity and histologic findings. JAMA. 256: 3117-3124, 1986. 47. Lotze, M.T., Rosenberg, S.A.: Results of clinical trials with the administration of interleukin-2 and adoptive immunotherapy with activated cells in patients with cancer. Immunobiology. 172: 420-437, 1986. 48. Lotze, M.T., Rosenberg, S.A.: Protocol design for lymphokine testing in clinical studies of human cancer. Lymphokine Res. 5: S177-S182, 1986. 49. Lotze, M.T, Custer, M.C., Rosenberg, S.A.: Intraperitoneal administration of interleukin-2 in patients with cancer. Arch. Surg. 121: 1373-1379, 1986. 50. Lotze, M.T.: Surgical considerations in the diagnosis and management of AIDS. AIDS Research. 2:141-148, 1986. (Reprint of 39) 51. Vetto, J.T., Papa, M.Z., Lotze, M.T., Chang, A.E., Rosenberg, S.A.: Reduction of toxicity of interleukin-2 and lymphokine activated killer cells in humans by the administration of corticosteroid. J. Clin. Oncol. 5:496-503, 1987. 25
  26. 26. 52. Lotze, M.T., Carrasquillo, J.A., Weinstein J.N., Bryant, G.J., Perentesis, P., Reynolds, J.C., Matis, L.A., Eger, R.R., Keenan, A.M., Hellstrom, I.,Hellstrom, K-E,Larson,S.M.:Monoclonal antibody imaging of human melanoma: Radio-immunodetection by subcutaneous or systemic injection.Ann. Surg. 204:223-35, 1986. 53. Skibber, J.M., Lotze, M.T., Seipp, C.A., Salcido, R., Rosenberg, S.A.: Limb sparing surgery for soft tissue sarcomas: Analysis of wound related morbidity. Surgery 102:447-452, 1987. 54. Roberts, K., Lotze, M.T., Rosenberg, S.A.: The lymphokine activated killer cell. Separation and functional studies of the human precursor and effector cell. Cancer Res. 47:4366-4371, 1987. 55. Lotze, M.T.: The role of lymph node dissection in the treatment of metastatic cancer to regional lymph nodes. (In): Surgical Cure of Metastatic Cancer. Rosenberg, S.A. (ed), J.B. Lippincott Co., Philadelphia, 1987. 56. Skibber, J.M., Lotze, M.T., Muul, L.M., Uppenkamp, I.K., Ross, W., Rosenberg, S.A.: Human lymphokine-activated killer cells: Further isolation and characterization of the precursor and effector cell. Nat. Immunity and Cell Growth Reg. 6:291-305, 1987. 57. Cohen, P.J., Lotze, M.T., Roberts, J.R., Rosenberg, S.A., Jaffee, E.S.: The immunopathology of sequential tumor biopsies in patients treated with interleukin-2. Correlation of response with T cell infiltration and HLA-DR expression. Amer. J. Pathol. 129:208-216, 1987. 58. Lee, R.E., Lotze, M.T., Skibber, J.M., Tucker, E., Bonow, R.O., Ognibene, F.P., Carrasquillo, J.A., Shelhammer, J.H., Parrillo, J.E., Rosenberg, S.A.: Cardiorespiratory effects of immunotherapy with interleukin-2. J. Clin. Oncol., 7:7-20, 1989. 59. Gaspari, A., Lotze, M.T., Rosenberg, S.A., Stern, J.B., Katz, S.I.: Cutaneous changes associated with interleukin-2 administration; Development of erythro-derma and cutaneous lymphocytic infiltration. J. Amer. Med. Association. 258:1624-1629, 1987. 60. Roberts, K., Lotze, M.T.: Interleukin-2 promotion of conjugate formation by purified LAK precursors and T lymphocytes: Enumeration of cell conjugates by flow cytometry. J. Biol. Resp. Mod. 7:249-266, 1988. 61. Lotze, M.T., Roberts, K., Custer, M.C., Segal, D.A., Rosenberg, S.A.: Specific binding and lysis of human melanoma by IL-2 activated cells coated with anti-T3 and Anti-Fc receptor crosslinked to anti-melanoma antibody: A possible approach to the immunotherapy of human tumors. J. Surg. Res. 42:580-589, 1987. 62. Skibber, J.M., Lotze, M.T., Uppenkamp, I., Ross, W., Rosenberg, S.A.: Identification and expansion of human lymphokine activated killer cells: Implications for the immunotherapy of cancer. J. Surg. Res. 42:613-621, 1987. 63. Lotze, M.T., Custer, M.C., Rosenberg, S.A.: Interleukin 2 (IL-2) administration to humans results in the rapid emigration of a specific lymphocyte subset (CD2+, 3-, 11+, 16+) from the peripheral blood. Unpublished. 26
  27. 27. 64. Denicoff, K.D., Rubinow, D.R., Papa, M.Z., Simpson, C., Seipp, C.A., Lotze, M.T., Chang, A.E., Rosenstein, D., Rosenberg, S.A.: The neuropsychiatric effects of IL-2/lymphokine activated killer cell treatment. Ann. Int. Med. 107:293-300, 1987. 65. Rosenberg, S.A., Lotze, M.T., Muul, L.M., Chang, A.E., Avis, F.P., Leitmann, S., Linehan, W.M., Robertson, C.N., Lee, R.E., Rubin, J.T., Seipp, C.A., Simpson, C.G., White, D.E.: Clinical experience with the treatment of 157 patients with advanced cancer using lymphokine activated killer cells and interleukin 2 or high dose interleukin-2 alone. NEJM, 316:889-905, 1987. 66. Lotze, M.T.: Biology of IL-2 and rationale for its clinical application. In Rosenberg, S.A., moderator. New approaches to the immunotherapy of cancer. Ann. Int. Med. 108:853-864, 1988. 67. Lotze, M.T. Treatment of hepatocellular carcinoma. In Dibisceglie, A.M., moderator. Hepatocellular carcinoma. Ann. Int. Med. 108:390-401, 1988. 68. Lotze, M.T., Rosenberg, S.A. Interleukin-2 as a pharmacologic reagent. Lymphokines, Ed.: Kendall Smith, Academic Press; NY, NY. 1988, pp237-294. 69. Rizzoni, W.E., Miller, K., Rick, M., Lotze, M.T. Heparin induced thrombocytopenia and thromboembolism in the perioperative period. Surgery 103: 470-476, 1988. 70. Cotran R., Pober JS, Gimbrone, Jr. M, Springer TA, Wiebke EA, Gaspari AA, Rosenberg SA, Lotze MT. Endothelial activation during interleukin-2 immunotherapy: A possible mechanism for the vascular leak syndrome. J. Immunol. 139:1883-88,1987. 71. Lotze, M.T., Rosenberg, S.A. Interleukin 2 therapy for disseminated cancer (letter to editor). JAMA 257:1729-1731. 1987. 72. Lee, R.E., Gaspari, A.A., Lotze, M.T., Chang, A.E., Rosenberg, S.A. Effects of interleukin-2 on psoriasis. Arch. Derm., 124:1811-1815, 1988. 73. Wiebke, E.A., Lotze, M.T., Rosenberg, S.A. Tumor cell susceptibility to lysis: Marked increase in lysis by tumor infiltrating lymphocytes following target stimulation with interferon-ã and tumor necrosis factor -ã. Implications for immunotherapy. Surgical Forum. 38:436-438, 1987. 74. Weinstein, J.N., Black, D.V., Holton, O.D. III, Covell, D.G., Parker, R.J., Mulshine, J.L., Lotze, M.T., Carrasquillo, J., Eger, R., Lewis, A., Larson, S.A., Keenan, A.M. Delivery of monoclonal antibodies to lymph nodes via the lymphatics. In: The Pharmacology and Toxicology of Proteins, Winkelhade, J.L., Holcenberg, J.S., Eds., NY: Alan R. Liss. 1988. 75. Lotze, M.T., Rosenberg, S.A. The Immunologic Treatment of Cancer. Ca-A Cancer Journal for Clinicians. 38:68-94, 1988. 76. Lotze, M.T., Ross, W.G., Tomita, S., Custer, M.C. Cells invading tumors: Strategies for the identific- ation and expansion of tumor reactive lymphocytes. Transplantation Proceedings. 20:326-331, 1988. 27
  28. 28. 77. Skibber, J.M,., Matter, G.J., Pizzo, P.A., Lotze, M.T. Right lower quadrant pain in young patients with leukemia: A surgical perspective. Ann. Surg, 206:711-716, 1987. 78. Wiebke, E.A., Rosenberg, S.A., Lotze, M.T. Cytokines alter target cell susceptibility to lysis: I. Evaluation of non-MHC restricted effectors reveals differential effects on natural and lymphokine-activated killing. J.Biol.Response Modifiers 9:113-126, 1990. 79. Jablons, D.M., Lotze, M.T. Derivation of cells with lytic activity against fresh and cultured tumors from human bone marrow. J. Surg. Res. 44:404-416, 1988. 80. Wiebke, E.A., Rosenberg, S.A., Lotze, M.T.: Acute immunologic effects of IL-2 in cancer patients: Decreased delayed type hypersensitivity response and decreased proliferative response to soluble antigens. J. Clin. Oncol. 6:1440-9, 1988. 81. Chang AE, Kinsella T, Glatstein E, Baker AR, Sindelar WF, Lotze MT, Danforth Jr. DN, Sugarbaker PH, Lack EE, Steinberg SM, White DE, Rosenberg SA. Adjuvant chemotherapy is effective for patients with high grade extremity sarcomas: Extended follow-up on treated patients. J. Clin. Oncol. 6:1491-1500, 1988. 82. Topalian, S.L., Solomon, D., Avis, F.P., Chang, A.E., Freerksen, D.L., Linehan, W.M., Lotze, M.T., Robertson, C.N., Seipp, C.A., Simon, P., Simpson, C.G., Rosenberg, S.A.: Immunotherapy of patients with advanced cancer using tumor infiltrating lymphocytes and recombinant interleukin-2: A pilot study. J. Clin. Oncol. 6:839-853, 1988. 83. Lotze, M.T.: Surgical management of hepatocellular carcinoma. Gastroenterology Clin. of N.A. 16:613-626, 1987. 84. Lotze, M.T., Tomita, S., Rosenberg, S.A.: Human tumor antigens defined by cytotoxic and proliferative T cells. In: Human Tumor Antigens and Specific Tumor Therapy. Eds. R. Metzgar and M.M Mitchell, 1988. 85. Lotze, M.T.: Book Review: "A history of surgery with emphasis on the Netherlands." By: D. De Moulin. Ann. Int. Med., 109:86-87, 1988. 86. Rosenberg, S.A., Longo, D.L, Lotze, M.T.: Principles of Biologic Therapy. In: Principles and Practices of Oncology. Eds. DeVita, V., Hellman, S., and Rosenberg, S.A. Lippincott, Philadelphia, 1989. pp. 301-348. 87. Del Vecchio, S., Reynolds, J.C., Carrasquillo, J.A., Blasberg, R.G., Neumann, R., Lotze, M.T., Bryant, G.J., Farkas, R.J., Larson, S.M.: Local distribution and concentration of 131I-9.2.27 monoclonal antibody in malignant melanoma following intravenous injection. Cancer Res. 49:2783-2789, 1989. 88. Begley, M.G., Shawker, T.H., Robertson, C.N., Wei, J., Bock, S., Lotze, M.T.: Fournier's gangrene: Diagnosis by scrotal ultrasound examination. Radiology. 169:387-389, 1988. 28
  29. 29. 89. Schwartzentruber, D., Lotze, M.T., Rosenberg, S.A.: Colonic perforation: An unusual complication of therapy with high-dose IL-2. Cancer. 62:2350-2353, 1988. 90. Jablons, D.M., Mule, J.J., McIntosh, J.K., Sehgal, P.B., May, L.T., Huang, C.M., Rosenberg, S.A., Lotze, M.T.: Interleukin-6/Interferon â-2 as a circulating hormone: Induction by cytokine administration in humans. J. Immunol., 142:1542-1547, 1989. 91. Kawakami, Y., Custer, M.C., Rosenberg, S.A., Lotze, M.T.: Interleukin-4 regulates Interleukin- 2 induction of lymphokine activated killer activity from human lymphocytes. J. Immunology. 142:3452-3461, 1989. 92. Kawakami, Y., Rosenberg, S.A., Lotze, M.T.: Interleukin-4 promotes the growth of tumor infiltrating lymphocytes specific for human autologous melanoma. J. Exp. Med., 168:2183- 2191, 1988. 93. Sakahara, H., Reynolds, J.C., Carrasquillo, J.A., Lora, M.E., Maloney, P.J., Larson, S.M., Neumann, R.D., Lotze, M.T.: In vitro complex formation and biodistribution of mouse antitumor monoclonal antibody in cancer patients. J. Nucl. Med., 30:1311-1317, 1989. 94. Rosenberg, S.A., Packard, B., Aebersold, P.M., Solomon, D., Topalian, S.L., Toy, S., Simon, P., Lotze, M.T., Yang, J.C., Seipp, C.A., Simpson, C., Carter, C., Bock, S., Schwartzentruber, D., Wei, J.P., White, D.E.: Immunotherapy of patients with metastatic melanoma using tumor infiltrating lymphocytes and Interleukin-2: Preliminary report. N. Engl. J. Med., 319:1676- 1680. 1988. 95. Rosenberg SA, Lotze MT, Yang JC, Topalian SL, Chang AE, Schwartzentruber DJ, Aebersold P, Leitman S, Linehan WM, Seipp CA, White DE and Steinberg SM. Prospective Randomized Trial of High-Dose Interleukin-2 Alone or In Conjunction with Lymphokine-Activated Killer Cells for the Treatment of Patients with Advanced Cancer. JNCI, 85: 622-632, 1993. 96. Stötter H., Wiebke E.A., Tomita S., Belldegrun A., Topalian S., Rosenberg S.A., Lotze M.T.: Cytokines alter target cell susceptibility to lysis: II. Evaluation of tumor infiltrating lymphocytes. J. Immunol., 142:1676-1773, 1989. 97. Denicoff, K.D., Durkin, T.M., Lotze, M.T., Quinlan, P.E., Davis, C.L., Listwak, S.J., Rosenberg, S.A., Rubinow, D.R.: The neuroendocrine effects of Interleukin-2 treatment. J. Clin. Endocrinology and Metabolism, 69:402-410, 1989. 98. Ognibene, F.P., Rosenberg, S.A., Lotze, M.T., Skibber, J., Parker, M.M., Shelhamer, J.H., and Parrillo, J.E.: Interleukin-2 administration causes reversible hemodynamic changes and left ventricular dysfunction similar to those seen in septic shock. Chest. 94:750-754, 1988. 99. Larson, ST., Carrasquillo, J., Reynolds, J., Deenan, A., Sugarbaker, P.,Colcher, D., Schlom, J., Neumann, R., Hellstrom, I., Hellstrom, K., Mulshine, J.,Lotze, M., and Strudler, P.: The NIH experience with radiolabeled monoclonal antibodies: lymphoma, melanoma, and colon cancer. In: Radiolabeled monoclonal antibodies for imaging and therapy, SC Srivastava, ed., Plenum Publishing Corp., New York, 1988. 29
  30. 30. 100. Jablons, D.M., McIntosh, J.K., Mule, J.J., Nordan, J.J., Rudikiff, S., and Lotze, M.T.: Induction of Interferon-B2/ Interleukin-6 (IL-6) by cytokine administration and detection of circulating IL- 6 in the tumor-bearing state In: Regulation of the Acute Phase and Immune Responses: A New Cytokine, Ed: Sehgal P.B., Grieninger, G., and Tosato, G., Ann. 557:157-162 Annals New York Acad. Science,1989. 101. McIntosh, J.K., Mule, J.J., Jablons, D.M., Nordan, R.P., Rudikoff, S., Lotze, M.T., Rosenberg, S.A.: The kinetics of IL-6 induction by systemic administration of rhTNF-á in mice. Annals New York Academy of Sciences, 557:572-575, 1989. 102. Lotze, M.T., Kawakami, Y., and Rosenberg, S.A.: Immunotherapy Protocols at the National Cancer Institute: Current Status and Future Prospects. Colloque Inserm 179:153-162, 1989. 103. Laue, L., Lotze, M.T., Chrousos, G.P., Barnes, K., Loriaux, L., and Fleisher,T.A.: Effect of chronic treatment with the glucocorticoid antagonist RU486 in man: toxicity, immunological and hormonal aspects. J. Clin. Endocrinol. 71:1474-80, 1990 104. Kasid, AT., Director, E., Stovroff, M.C., Lotze, M.T., Rosenberg, S.A.: Cytokine regulation of tumor necrosis factor-á and â (lymphotoxin)- messenger RNA expression in human peripheral blood lymphocytes. Cancer Res. 50: 5072-6, 1990. 105. Fisher, B., Keenan, A., Garra, B.S., Steinberg, S.M., White, D.E., DeBisceglie, A.M., Hoofnagle, J.H., Yolles, P., Rosenberg, S.A., Lotze, M.T.: Interleukin-2 induces profound reversible cholestasis: A detailed analysis in treated patients. J. Clin. Oncol. 7:1852-1862, 1990. 106. Rosenberg, S.A., Lotze, M.T., Yang, J.C., Linehan, W.M., Seipp, C., Calabro, S., Karp, S.E., Sherry, R.M., Steinberg, White, D.E.: Combination therapy with Interleukin-2 and Alpha- Interferon for the treatment of patients with advanced cancer. J. Clin. Oncology 7:1863-1874, 1989. 107. Ward, B., McGarvey, C., Lotze, M.T.: Functional outcome following partial or total scapulectomy/Analysis at prolonged follow-up. Arch Surg. 124:537-542, 1989. 108. Bock, S.N., Lee, R.E., Fisher, B., Rubin, J.T., Schwartzentruber, D., Wei, J.P., Callender, D., Yang, J.C., Lotze, M.T., Pizzo, P.A., Rosenberg, S.A.: A prospective randomized trial evaluating prophylatic antibiotics to prevent catheter-related sepsis in patients treated with immunotherapy. J Clin Oncol 8:161-169, 1990. 109. Wade, TP, Lotze, MT: Lymph stasis after lymph node dissection.In: Lymph Stasis: Pathophysiology, Diagnosis, and Treatment, WL Olszewski Ed. Year Book Pub 1991. 110. Custer, M.C., Lotze, M.T.: A biologic assay specific for Interleukin-4: Rapid Fluorescence Assay for IL-4 detection in supernatants and serum, J. Imm. Methods, 128: 109-17, 1990. 111. Lotze, M.T.: Letter to the editor; High output cardiac failure in patients with multiple myeloma. New Eng. J. of Medicine, 320:1419, 1989. 30
  31. 31. 112. Rubin, J.T., Elwood, L., Rosenberg, S.A., Lotze, M.T.: Immunohistochemical Correlates of Response to Recombinant Interleukin-2 Based Immunotherapy, Cancer Research, 49:7086-7092, 1989. 113. Jablons, D., Bolton, E., Mertins, S., Rubin, M., Pizzo, P., Rosenberg, S.A., Lotze, M.T.:Interleukin-2 Based Immunotherapy Alters Circulating Neutrophil Fc Receptor Expression and Chemotaxis. J. Immunology, 144:3630-3636, 1990. 114. Culver, K., Cornetta, K., Morecki, S., Aebersold, P., Freeman, S., Kasid, A., Morgan, R., Lotze, M.T., Rosenberg, S.A., Anderson, W.F., Blaese, R.M.: Gene Therapy: Lymphocytes As Cellular Vehicles For Gene Transfer In Mouse And Man. Proc.Nat.Acad.Sci. 88:3155-3159, 1992. 115. Kragel, A.H., Travis, W.D., Feinberg, L., Pittalugia, S., Striker, L.M., Roberts, W.C., Lotze, M.T., Yang, J.J., Rosenberg, S.A.: Pathologic Findings Associated with Interleukin-2 Based Immunotherapy For Cancer: A Postmortem Study of 19 Patients. Human Pathology, 21:493- 502, 1990. 116. Rosenberg, S.A., Lotze, M.T., Yang, J.C., Aebersold, P.M., Linehan, W.M., Seipp, C.A., White, D.E.: Experience With The Use Of High Dose Interleukin-2 In The Treatment Of 652 Patients With Cancer. Ann. Surg, 210:474-485, 1989. 117. Huang, C.M., Ruddle, M., Sliva, C., Elin, R.J., Lotze, M.T., Rosenberg, S.A.: Changes In Laboratory Results With Interleukin-2 Therapy Administered To Cancer Patients. Clin. Chemistry, 36:431-434, 1990. 118. Lotze, M.T.: Interleukin-2 Based Immunotherapy Of Malignant Melanoma, in Therapy of Advanced Melanoma Ed. P. Rumke, S. Karger AG, Basel, Pigment Cell 10: 163-182, 1990. 119. McIntosh, J.E., Jablons, D.M., Mule, J.J., Nordan, R. P., Rudikoff, S., Lotze, M.T., Rosenberg, S.A.: In Vivo Induction of IL-6 by Administration of Exogenous Cytokins and Detection of De Novo Serum Levels of IL-6 in Tumor-Bearing Mice. J. Immunology., 143:162-167, 1989. 120. Kasid, A., Morecki, S., Aebersold, P., Cornetta, K., Culver, K., Freeman, S., Director, E., Lotze, M.T., Blaese, R.M., Anderson, F., Rosenberg, S.A.: Human Gene Transfer: Characterization of human tumor infiltrating lymphocytes as vehicles for retroviral mediated gene transfer in man. Pro. Nat. Acad. Sci., 87:473-477, 1990. 121. Rubin, J.T., Rosenberg, S.A., Lotze, M.T.: The efficacy of high dose IL-2 based immunotherapy in man. in Rees RC Ed IRL Press, pp. 139-159, 1990. The Biology and Clinical Applications of Interleukin-2. 122. Stotter, H., Lotze, M.T.: Cytolytic effector cells against human tumors: Distinguishing phenotype and function. Cancer Cells, 2:44-56, 1990. 123. Lotze, M.T., Custer, M.C., Bolton, E.S., Wiebke, E.A., Kawakami, Y., Rosenberg, S.A.: Mechanisms of immunologic antitumor therapy: lessons from the laboratory and clinical 31
  32. 32. applications. Human Immunology, 28:198-207, 1990. 124. Lotze, M.T., Jablons, D.M., Rubin, J.T., Chang, A.E., Rosenberg, S.A.: Cytokine therapy of patients with cancer. Progress In Immunology, 7:1213-1220, 1990. 125. Jablons DM, Donohue R, Kawakami Y, Young JD, Lotze MT. Interleukin-3 induces proliferation but not lymphokine activated killer activity from human and murine mononuclear cells. Eur Cytokine Netw. 1990 May-Jun;1(2):91-8. 126. Kawakami, Y., Haas, G.P., Lotze, M.T.: Expansion of Tumor Infiltrating Lymphocytes from Human Tumors Using the T cell Growth Factors Interleukin-2 and Interleukin-4. J. Immunotherapy 14:336-47, 1993. 126a. Lotze, M.T.: Biological Response Modifiers in Cancer Therapy (book review). Immunology Today, 11:143, 1990. 127. Lotze, M.T.: Interleukin-2-Basic Principles, in Principles and Practice of Biologic Therapy, DeVita, V., Hellman, S., Rosenberg, S.A. J Lippincott, Phila., 1991. 128. Lotze, M.T.: Cancer Treatment with Interleukin-2, Principles and Practice of Biologic Therapy, ed DeVita, V, Hellman, S., Rosenberg, S.A. J Lippincott, Philadelphia, 1991. 129. Lotze, M.T.: Disturbing Homeostasis: Recent results of ongoing immunotherapy trials at the NCI. Biotechnology Therapeutics, 1:125-162, 1989. 130. Lotze, M.T.: Book Review, Biologic Response Modifiers in Cancer Therapy. Immunology Today. 11:143, 1990. 131. Lotze, M.T.: Preface - Current paradigms in cellular immunology: Implications for immunity to cancer. In Cellular Immunology and the Immunotherapy of Cancer. ed Lotze, M.T. and Finn, O., Wiley-Liss, New York, 1990. 132. Lotze, M.T., Custer, M.C., Kawakami, Y., Stotter, H.,Rubin, J.T., Bolton, E.S., Guedez, L. and Sanda, M.G.: T cell growth factors and the expansion of lymphoid cells with antitumor activity in vitro and in vivo. In Cellular Immunity and the Immunotherapy of Cancer. eds. Lotze, M.T. and Finn, O.J. Wiley-Liss, New York, 1990. 133. Stötter, H., Custer, M.C., Bolton, E.S., Guedez, L. and Lotze, M.T.: Interleukin-7 induces human lymphokine activated killer (LAK) cells and is regulated by interleukin-4. J. Immunol 146: 150-144, 1991. 134. Lotze, M.T. and Finn, O.J.: Current Paradigms In Cellular Immunity: Implications for immunity to cancer. Immunology Today. 11:190 - 3, 1990 135. Lotze, M.T. and Rosenberg S. A.: The Use of Lymphokines in therapy, in Progress in Allergy and Clinical Immunology ed. W.J. Pickles, B. M. Stadler, C. Dahinden et al; Hogrefe & Huber, Toronto pp. 529-536, 1989. 32
  33. 33. 136. Rosenberg, S.A., Aebersold, P., Cornetta, K., Kasid, A., Morgan, R.A., Moen, R., Karson, E.M., Lotze, M.T., Yang, J.C., Topalian, S.L., Merino, M.J., Culver, K., Miller, A.D., Blaese, R.M. and Anderson, W.: Gene transfer into humans: Immunotherapy of patients with advanced melanoma using tumor infiltrating lymphocytes modified by retroviral gene transduction. N. Engl. J. Med. 323: 570-578, 1990. 137. Stötter, H. and Lotze, M.T.: Human Lymphokine Activated Killer Activity: Role of Interleukin-2, Interleukin-4, and Interleukin-7. Arch Surg 126:1525-30, 1991. 138. Aebersold, P., Hyatt, S., Johnson, S., Hinesk, Korcak, L., Sanders, M., Lotze, M., Topalian, S., Yang, J. and Rosenberg, SA: Lysis of autologous melanoma cells by tumor infiltrating lymphocytes: Association with clinical response. Journal of the National Cancer Institute, 83: 932-937, 1991. 139. Feuerstein, I. M., Chow, C. K., Miller, D.L., Carrasquillo.J.A., Lotze, M.T., Radiologic Findings in Hepatocellular Carcinoma: The National Institutes of Health Experience in Hepatocellular Carcinoma, Ed. Tabor E, DiBesceglie A and Purcell RH. pp. 255-272, 1991. 140. Spencer W. F., Linehan, W. M., Walther, M.M., Lotze, M.T., Topalian, S., Yang, J., Merino, M. J., Lange, J. R., Pockaj, B.A., and Rosenberg, S.A.: The Role of Pre-nephrectomy IL-2 based immunotherapy in patients with metastatic renal cell carcinoma, J. Urology.147:24-30, 1992. 141. Wong, H. L., Lotze, M.T., Wahl, L.M., Wahl, S.M.: Administration of recombinant IL-4 to humans regulates gene expression, phenotype, and function in circulating monocytes. J. Immunol. 148:2118-2125, 1992. 142. Lotze, M.T.: T cell growth factors and the treatment of patients with cancer. Clinical Immunology and Immunopathology 62:s47-s54, 1992. 143. Edington, H.D., and Lotze, M.T.: Immunotherapy of human sarcomas. Postgraduate General Surgery 3:36-41, 1991. 144. Lotze, M.T.: Interleukin-2 in Human Cytokines, ed Aggarwal BB, Gutterman JV, Blackwell Scientific Publications, Cambridge, 1991. 145. Rubin J. T. and Lotze M.T.: Acute Gastric Mucosal Injury Associated with Systemic Administration of Interleukin-4. Surgery 111:274-280, 1991. 146. Lotze, M.T.: Concerning repeat hepatic resections for colorectal cancer (letter to editor) Surgery 109:347-348, 1991. 147. Lotze, MT. Healing Arts (journal review article-Biotherapy and Molecular Biotherapy) Nature 347: 587-588, 1990. 148. Lotze MT and Kramarski CM. Shoulder immobilizer for axillary nodal dissection: A "safe" device. Contemporary Oncology, 1991. 33
  34. 34. 149. Lotze MT. Sui Generis (journal review article). Nature 1991. 150. Lotze MT. Role of IL-4 in the antitumor response in H. Spits,ed. Interleukin-4 Raven Press, 1992, Chapter 15, 237-262. 151. Choyke PL, Miller DL, Lotze MT, Whiteis J, Ebbat B, and Rosenberg SA. Delayed reaction to intravenous contrast media following Interleukin-2 immunotherapy. Radiology 183:111-114, 1992. 152. Lotze MT. Trials and Tribulations: The Cost of Developing Gene Therapies (Editorial) FASEB Jl 5:3013-3014, 1991. 153. Emery BE, Igarashi Y, White MV, Mullol J, Berkebile C, Peden D, Lotze MT, and Kaliner MA. The effect of IL-4 Upon Human Nasal Mucosal Responses. Jl Allergy and Clinical Immunology, 90:772-81, 1992. 154. Lotze MT. Clinical Protocol: The treatment of patients with melanoma using IL-2, IL-4, and tumor infiltrating lymphocytes. Human Gene Therapy, 3: 167-177, 1992. 155. Lotze MT, Zeh HJ, Elder EM, Cai Q, Pippin BA, Whiteside TL and Herberman RB. Use of T- cell Growth Factors (IL-2 to IL-12) in the investigation and treatment of melanoma. J. Immunotherapy, 12: 212-217, 1992 156. Weidmann E, Elder EM, Trucco M, Lotze MT, and Whiteside TL. Usage of the T-Cell receptor Vâ chain genes in fresh and cultured tumor-infiltrating lymphocytes from human melanoma. Int. J. Cancer 54:383-390, 1993. 157. Tahara H, Mueller GM, Ricordi C, Robbins PD, Lotze MT. Islet cell transplantation facilitated by gene transfer. Transplant. Proc. 24:2975-2976, 1992. 158. Wong HL,Costa GL, Lotze MT,Wahl SM.IL-4 differentially regulates monocyte IL-1 family gene expression and synthesis in vitro and in vivo. J Exp Med177:775-81,1993. 159. Richards JM and Lotze MT. Interleukin-2 Therapy:Current Status and Future Directions. Contemporary Oncology 2:34-44, 1992. 160. Lotze MT. Keystone Symposium. Melanoma and Biology of the Neural Crest. Melanoma Res, 2:131-138, 1992. 161. Lange JR, Raubitschek AA, Pockaj BA, Spencer WF, Lotze MT, Topalian SL, Yang JC and Rosenberg SA. A pilot study of combination of Interleukin-2 based immunotherapy and radiation therapy. J. Immunotherapy, 12: 265-271, 1992. 162. Sanda MG, Yang JC, Topalian SL, Groves ES, Childs A, Rubens R, deSmet MD, Schwartzentruber DJ, White DE, Lotze MT and Rosenberg SA. Intravenous administration of recombinant human macrophage colony-stimulating factor to patients with metastatic cancer: A 34
  35. 35. Phase I Study. J Clin Onc, 10: 1643-1649, 1992. 163. Rubin JT, Duquesnoy R, Day R, Simonis TB, Rosenberg SA and Lotze MT. HLA-DQ1 is associated with clinical response and prolonged survival of patients with melanoma who are treated with interleukin-2 based immunotherapy in humans. Therapeutic Immunology, 2:1-6, 1995. 164. Lotze MT, Carr B and Flickenger J. Hepatobiliary Neoplasms in Principals and Practices of Oncology, Rosenberg, DeVita and Hellman (ed) J. B. Lippincott, 883-914, 1993. 165. Miller DL and Lotze MT. A Plea for a Standard Standard. Intraarterial chemotherapy for hepatic neoplasms. Radiology 188:19-20, 1993. 166. Itoh I, Storkus WJ, Gorelik E and Lotze MT. Partial purification of murine tumor-associated peptide epitopes common to histologically disticnt tumors, melanoma and sarcoma that are presented by H-2Kb and recognized by CD8+ Tumor Infiltrating Lymphocytes. J Immunology 153:1202-15, 1994. 167. Lotze MT, Storkus WJ, Hurd SD, Maeurer MJ, Kirkwood JM. Immunotherapy of melanoma. Melanoma Research 3:5-6, 1993. 168. Edington H and Lotze MT. Immunotherapy, in Colorectal Cancer, ed. HJ Wanebo, Mosby, St. Louis, pp540-564, 1993. 169. Edington HD and Lotze MT. Cellular Immunotherapy for Colorectal Cancer.in Cohen AM, Winawer SJ, Friedman MA, Gunderson LL (editors), Cancer of the Colon, Rectum and Anus; McGraw-Hill, Inc., NY, pp949-959, 1995. 170. Robbins PD, Tahara H, Mueller G, Hung G, Bahnson A, Zitvogel L, Galea-Lauri J, Ohashi T, Patrene K, Boggs SS, Evans CH, Barranger JA and Lotze MT. Retroviral Vectors for use in Human Gene Therapy for Cancer, Gaucher Disease, and Arthritis. Annals of the New York Acad. Sci.716:72-88, 1994. 171. Zeh HJ, Hurd S, Storkus WJ, and Lotze MT. Interleukin 12 Promotes the Proliferation and Cytolytic Maturation of Immune Effectors: Implications for the Immunotherapy of Cancer. J Immunotherapy 14:155-161, 1993. 172. Zeh HJ, Tahara H, and Lotze MT. Interleukin-12. Chapter 13 in The Cytokine Handbook, Second Edition; pp 239-256; Editor, A. Thomson, Academic Press, Ltd; London; 1994. 173. Nastala CL, Edington HD, Storkus WJ and Lotze MT. Recombinant Interleukin-12 (r-mIL-12) Mediates Regression of Both Subcutaneous and Metastatic Murine Tumors. Surgical Forum 44:518-521, 1993. 174. Nastala CL, Edington H, Storkus W, McKinney TG, Brunda M, Gately M, Wolf SF, chrieber R and Lotze MT. Recombinant Interleukin-12 Induces Tumor Regression in Murine Models: Interferon-Gamma But Not Nitric Oxide Dependent Effects. J. Immunol 153,:1697-1706, 1994. 35
  36. 36. 36
  37. 37. 175. Tahara H, Zeh H, Storkus WJ, Pappo I, Watkins S, Gately MK, Gubler U, Wolf SF, Robbins PD and Lotze MT. Fibroblasts Genetically Engineered to Secrete Interleukin-12 can Suppress Tumor Growth In Vivo and Induce Antitumor Immunity To A Murine Melanoma. Cancer Res. 54:182- 189, 1994. 176. Lotze MT. Transplantation and Adoptive Cellular Therapy of Cancer: The Role of T cell Growth Factors. Cell Transplantation, 2:33-47, 1993. 177. Storkus W. J., Zeh III, H. J., Salter R. D., Lotze, M. T. Identification of T cell epitopes: Rapid isolation of class I-presented peptides from viable cells by mild acid elution. J. Immunother.14:94-103, 1993. 178. Storkus W. J., Zeh III, H. J., Salter R. D., Lotze, M. T. Isolation of human melanoma peptides recognized by class I restricted tumor infiltrating T lymphocytes. J. Immunol.151:3719-3727, 1993. 179. Lotze MT, Rubin JT and Zeh HJ. New Biologic Agents Come to Bat for Cancer Therapy. Current Science, 4: 1116-1123, 1992. 180. Marincola FM, Venzon D, White D, Rubin JT, Lotze MT, Simonis TB, Balkisson J, Rosenberg SA, Parkinson DR. HLA association with response and toxicity in melanoma patients treated with interleukin-2 based immunotherapy. Cancer Research 52:6561-6, 1992. 181. Rubin JT, Lotze MT. Immune function and dysfunction. A primer for the Radiologist. Radiologic Clinics of North America 30:507-23, 1992. 182. White MV, Igarashi Y, Emery BE, Lotze MT, Kaliner MA. Effects of in vivo administration of interleukin-2 (IL-2) and IL-4 alone and in combination, on ex vivo human basophil histamine release. Blood 79:1491-5, 1992. 183. Oppenheim MH, Lotze MT. Interleukin-2: Solid Tumor Therapy. Oncology 51:154-69, 1994. 184. Leder GH, Oppenheim M, Rosenstein M, Shah N, Hoffman R, Lotze MT, Beger HG. Inhibition of nitric oxide synthesis does not improve Interleukin-2-mediated antitumor effects in vivo. Eur Surg Res 28:167-78, 1996. 185. Lotze MT, Finn OJ. Cellular immunity and the immunotherapy of cancer. J.Immunother. 14:79-87, 1993. 186. Lotze MT, Agarwala SS, Kirkwood JM.Clinical Development of IL-2. Oncology 1993. 187. Zeh HJ, Salter RD, Techtor M, Leder G, Stuber G, Modrow S, Lotze MT, Storkus WJ. Flow cytometric determination of peptide-Class I complex formation: Identification of p53 peptides binding HLA-A2. Human Immunology 39:79-86, 1994. 188. Hunt JD, Pippin AB, Landreneau RJ, Jacob WF, Lotze MT, Siegfried JM. Transfer and expression of the human Interleukin-4 gene in carcinoma and stromal cell strains derived from lung cancer patients. J Immunotherapy 14:314-21, 1993. 37
  38. 38. 189. Irshaid Y, Adedoyin A, Lotze M, Branch R. Monoacetyldapsone inhibition of dapsone hydroxylation by human and rat liver microsomes. Drug Metab.Disp. 22:161-4, 1994. 190. Leder GH, Storkus WJ, Zeh HJ, Lotze MT. Can p53 peptides serve as tumor-specific antigens? Peptides 1992, Ed. SH Schneider, AN Eberle. ESCIM Science Pub. 1993. 191. Rosenberg SA, Lotze MT, Yang JC, Topalian SL, Chang AE, Schwartzentruber DJ, Aebersold P, Leitman S, Linehan WM, Seipp CA et al.Prospective randomized trial of high-dose IL-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. Jl. Nat. Cancer Inst. 85:622-32, 1993. 192. Edington HD, Lotze MT. Interleukin 7 in Cytokine Handbook, ed. Angus Thompson, 1994. 193. Lotze MT. Biologic Response Modifiers and the Treatment of Infectious Diseases in Surgical Infectious Diseases 3rd Edition; ed. RJ Howard, RL Simmons, 1994; Appleton and Lange, Norwalk, CN; pp 595-616. 194. Lotze MT. Molecular biology and clinical applications to cancer. Curr. Opinion in General Surgery 2:245-254, 1994. 195. Lotze MT. What's New in Surgical Oncology. Bull. Amer. Coll. Surg.79:42-47, 1994. 196. Pappo I, Tahara H, Nishihara K, Robbins PD, Gately MK, Wolf SF, Lotze MT. Administration of systemic or local interleukin-2 enhances the antitumor effects of interleukin-12 gene therapy. J. Surg. Res, 57:218-226, 1995. 197. Lotze MT. Soft Tissue Sarcomas: Diagnosis and Treatment Ed. John H. Raaf (Book Review). N. Engl. J. Med. 329:1284-1285, 1993. 198. Qin L, Chavin KD, Tahara H, Robbins PD, Lotze MT, Favarro J, Woodward J, Ding Y, Bromberg JS. Retrovirus-Mediated Transfer of Viral Interleukin-10 Gene Prolongs Murine Cardiac Allograft Survival. J Immunology 156:2316-2324, 1996. 199. Leder GH, Oppenheim M, Rosenstein M, Shah N, Hoffman R, Simmons R, Lotze MT. The IL-2 induced nitric oxide production but not the IL-2 induced capillary leak syndrome is decreased by aminoguanidine.3rd International Nitric Oxide Mtg. 200. Stuber G, Leder GH, Storkus WJ, Lotze MT, Modrow S, Szekely L, Wolf H, Klein E, Karre K, and Klein G. Identification of wild-type and mutant p53 peptides binding to HLA-A2 assessed by a peptide loading deficient cell line assay and a novel MHC Class I peptide binding assay. Eur. J. Immunol. 24:765-8, 1994. 201. Maeurer MJ, Hurd S, Martin D, Storkus WJ,, Lotze MT. Cytolytic T-cell clones define HLA-A2 restricted human cutaneous melanoma peptide epitopes - correlation with T-cell receptor usage. The Cancer Journal 2:162-170, 1995. 38
  39. 39. 202. Maeurer MJ, Storkus WJ, Lotze MT. Tumor Vaccines. Principles of Clinical Immunology, Robert Rich, Editor, 1995. 203. Shaw S, Luce GG, Gilks WR, Anderson K, Ault K, Bochner BS, Boumsell L, Denning SM, Engleman EG, Fleisher T, Freedman AS, Fox DA, Gailit J, Gutierrez-Ramos JG, Hurtubise PE, Lansdorp P, Lotze MT, Mawhorter S, Marti G, Matsuo Y, Minowda J, Michelson A, Picker L, Ritz J, Roos E, van der Schoot CE, Springer TA, Tedder TF, Telen MJ, Thompson JX, Valent P. Leukocyte differentiation antigen database. in Leukocyte Typing V; edited by Schlossman S, Boumsell L, Gilks W, Harlan J, Kishimoto T, Morimoto C, Ritz J, Shaw S, Silverstein R, Springer T, Tedder T, and Todd R. Oxford University Press, 1994. 204. Pockaj BA, Yang JC, Lotze MT, Lange JR, Spencer WF, Steinberg SM, Topalian SL, Schwartzentruber DJ, White DE, Rosenberg SA. A prospective randomized trial evaluating colloid versus crystalloid resuscitation in the treatment of the vascular leak syndrome associated with Interleukin-2 therapy. J. Immunotherapy 15:22-28, 1994. 205. Zitvogel L, Tahara H, Robbins PD, Storkus WJ, Wolf SF, Gately M, Lotze MT.Construction and characterization of retroviral vectors expressing biologically active human Interleukin 12 (IL- 12). Human Gene Therapy 5:1493-1506, 1994. 206. Tahara H, Lotze MT. Antitumor effect of interleukin-12 (IL-12): Applications for the immunotherapy and gene therapy of cancer. Gene Therapy 2:96-106, 1995. 207. Thomson AW, Lotze MT. Interleukins 13-15. Chapter 14; pp 257-264 in The Cytokine Handbook, Second Edition; Editor, A. Thomson, Academic Press, Ltd; London; 1994. 208. Pippin BA, Rosenstein M, Jacob WF, Chiang Y, Lotze MT. Local IL-4 delivery enhances immune reactivity to murine tumors: gene therapy in combination with IL-2. Cancer Gene Therapy, 1:1-7, 1994. 209. Lotze MT, Rubin JT. Gene Therapy of Cancer: A pilot study of IL-4-gene-modified fibroblasts admixed with autologous tumor to elicit an immune response. Human Gene Therapy 5:41-56, 1994. 210. Strumph PS, Carty SE, Rilo HLR, Carroll PB, Ricordi C, Lotze MT. Interleukin-1 receptor antagonist is not detrimental to human islet cell insulin secretion but decreases insulin content. Transplantation Proceedings 26: 694, 1994. 211. Qin L, Chavin KD, Ding Y, Favaro JP, Woodward JE, Lin J, Tahara H, Robbins P, Shaked A, Ho D, Sapolsky R, Lotze MT, Bromberg JS. Multiple vectors effectively achieve gene transfer in a murine cardiac transplantation model. Transplantation 59:809-816, 1995. 212. Nishihara K, Barth RF, Wilkie N, Lang JC, Oda Y, Kikuchi H, Everson MP, Lotze MT. Increased in vitro and in vivo tumoricidal activity of a genetically engineered macrophage cell line by an exogenous IFN-ã, IL-4, IL-6 or TNF-á gene expression. Cancer Gene Therapy, 2:113- 124, 1995. 39
  40. 40. 213. Storkus WJ, Lotze MT. Biology of Tumor Antigens. B. Tumor Antigens Recognized by Immune Cells. In Biologic Therapy of Cancer, ed. DeVita V, Hellman S, Rosenberg SA. JB Lippincott, Phila. 1995. 214. Nastala CL, McKinney BA, Edington HD, Tahara H, Gately MK, Storkus WJ, Lotze MT. Interleukin-12 (IL-12) induces specific anti-tumor immunity in animals bearing established subcutaneous murine sarcoma. Surgical Forum, 80:492-494, 1994. 215. Höhnke C, Nastala CL, Tahara H, Suzuki T, Edington HD, Lotze MT. The use of gene transfer of viral IL-10 to facilitate allogeneic skin transplantation. Surgical Forum, 80:776-779, 1994. 216. Castelli C, Storkus WJ, Maeurer MJ, Martin DM, Huang EC, Pramanik BN, Nagabushan TL, Parmiani G, Lotze MT. Mass spectrometric identification of a naturally-processed melanoma peptide recognized by CD8+ cytotoxic T lymphocytes. J Exp Med,181:363-368, 1995. 217. Lotze MT. Interleukin 2 - Preclinical Studies. In Biologic therapy of Cancer, Ed. Devita V., Hellman S, Rosenberg SA. JB Lippincott, Phila. 1995. 218. Maeurer MJ, Martin DM, Castelli C, Elder E, Leder E, Storkus WJ, Lotze MT. Host immune response in renal cell cancer. IL-4 and IL-10 mRNA are frequently detected in freshly collected tumor infiltrating lymphocytes. Cancer Immunology and Immunotherapy 41:11-121, 1995. 219. Maeurer MJ, Storkus WJ, Lotze MT. New avenues of cancer treatment: Modulation of host anti- tumor directed immune responses by IL-4 and IL-12 in renal cell cancer. In Biology of Renal Cell Carcinoma, Ed. RM Bukowski, JH Finke, Klein EA.Springer-Verlag, New York, pp161- 174, 1995. 220. Cai Q, Rubin JT, Lotze MT. Genetically marking human cells - Results of the first clinical gene transfer studies. Cancer Gene Therapy, 2:125-136, 1995. 221. Tahara H, Zitvogel L, Storkus WJ, Zeh HJ, McKinney TG, Schreiber RD, Gubler U, Gately MK, Robbins PD, Lotze MT. Effective eradication of established murine tumors with therapy using a polycistronic retroviral vector. J. Immunol. 154:6466-6474, 1995. 222. Chavin KD, Qin L, Tahara H, Robbins PD, Lotze MT, Bromberg JS. Gene transfer of TGF-â and viral IL-10 prolong cardiac allograft survival. Surg. Forum 44:404-9,1993. 223. Frassanito MA, Mayordomo JI, DeLeo RM, Storkus WJ, Lotze MT, DeLeo AB. Identification of Meth A sarcoma-derived class I MHC-associated peptides recognized by a specific CD8+ CTL. Cancer Research 55:124-128, 1995. 224. Lotze MT, Rubin JT, Whiteside TL, Herberman RB. Cytokine and Cellular Mediated Immunotherapy of Cancer. Chapter 122 in Principles of Clinical Immunology, pp1919-1930; Robert Rich, Editor, Mosby Yearbook, Inc., St. Louis, 1996. 225. Tahara H, Lotze MT. Gene Therapy for Adult Cancers: Advances in Immunologic Approaches Using Cytokines. Chapter 15 in Somatic Gene Therapy, pp 263-286; Patricia L. Chang, Editor, CRC Press, Inc. Boca Raton, FL, 1994. 40
  41. 41. 226. Suzuki T, Tahara H, Robbins P, Narula S, Moore K, Lotze MT. The human herpes virus 4 cIL- 10 homologue, vIL-10 induces local anergy to tumor allo and autografts. J. Exp. Med.182:477- 486, 1995. 227. Zitvogel L, Tahara H, Robbins PD, Storkus WJ, Clark M, Nalesnik M, Gately M, Lotze MT. Cancer immunotherapy of established tumors with Interleukin-12 (IL-12): Effective delivery by genetically engineered fibroblasts. J. Immunology 155:1393-1403, 1995. 228. Di Bisceglie AM, Simpson LH, Lotze MT, Hoofnagle JH. Development of hepatocellular carcinoma among patients with chronic liver disease due to Hepatitis C viral infection. J Clin Gastroenterol 19:222-226, 1994. 229. Schwarz RE, Reynolds JC, Lotze MT. "Pseudo-pseudotumor" of the liver. Adenocarcinoma presenting as an inflammatory pseudotumor. Digestive Diseases & Sciences 39:2679-84, 1994. 230. Goydos JS, Lotze MT. Biologic Therapy: Current and Future Considerations. Chapter 73 in Surgery for Gastrointestinal Cancer: A Multidisciplinary Approach. pp831-848, Harold J. Wanebo, editor; Lippincott-Raven Publishers; Philadelphia; 1997. 231. Suminami Y, Elder EM, Lotze MT, Whiteside TL. In situ IL-4 gene expression in cancer patients treated with a genetically-modified tumor vaccine. Journal of Immunotherapy 17:238- 248, 1995. 232. Elder EM, Lotze MT, Whiteside TL. Successful culture of cytokine gene-modified human dermal fibroblasts for biologic therapy of patients with cancer. Human Gene Therapy 7:479-487, 1996. 233. Mayordomo JI, Zorina T, Storkus WJ, Celluzzi C, Falo LD, Melief CJ, Ildstad ST. Kast WM, DeLeo A, Lotze MT. Bone marrow-derived dendritic cells pulsed with tumor peptides effectively treat established murine tumors. Nature - Medicine 1(12):1297-1302, 1995 234. Myers JN, Yasumura S, Suminami Y, Hirabayashi H, Lin W-C, Johnson JT, Lotze MT and Whiteside TL. Growth stimulation of human head and neck squamous cell carcinoma cell lines by Interleukin-4.Clin. Cancer Research 2:127-136, 1996. 235. Maeurer MJ, Wolter W, Zitvogel L, Storkus WJ, Lotze MT. The role of Interleukin-7 in the expansion of colon cancer - specific and MHC Class II restricted tumor infiltrating lymphocytes (TIL) in vitro and in vivo. Cancer Gene Therapy, 1995 236. Maeurer MJ, Storkus WJ, Kirkwood JM, Lotze MT. Immunization with melanoma derived peptide T-cell epitopes represents a new treatment option for patients with melanoma. Melanoma Research,6:11-24, 1996. 237. Maeurer MJ, Martin D, Elder E, Storkus WJ, Lotze MT. Detection of naturally processed and HLA-A1 presented melanoma T-cell epitopes defined by CD8+ T-cells releasing GM-CSF, but not mediating target cytolysis. Clinical Cancer Research 2:87-96, 1996. 41
  42. 42. 238. Maeurer MJ, Gollin S, Storkus WJ, Swaney W, Martin D, Castelli C, Salter R, Knuth A, Lotze MT. Tumor escape from immune recognition.Loss of HLA-A2 melanoma cell surface expression is associated with a complex rearrangement of the short arm of chromosome 6. Clin. Cancer Res. 2:641-652, 1996. 239. Celluzzi CM, Mayordomo JI, Storkus WJ, Lotze MT, Falo LD. Peptide-pulsed dendritic cells induce antigen specific CTL-mediated protective tumor immunity. J Exp Med 183:283-287, 1996. 240. Zitvogel L, Mayordomo JI, Tjandrawan T, DeLeo AB, Clarke ML, Lotze MT, Storkus WJ. Therapy of Murine Tumors with Tumor Peptide-pulsed Dendritic Cells: Dependence on T Cells, B7 Costimulation, and T Helper Cell 1-associated Cytokines. J Exp Med 183:87-97, 1996. 241. Rubin JT, Lotze MT, Rosenfelder D, Brumfield A, Howells R, Schwartz R, Sylvestri S, Sammon J, Bron K, Orens P, Zajko A, Swanson D, Day R. Treatment of hepatic-metastatic colorectal cancer with a chemotherapeutic emulsion: interim results of a phase I trial. Ann Surg Oncol 2:351-359, 1995. 242. Zitvogel L, Lotze MT. Role of Interleukin-12 (IL-12) as an antitumor agent: Experimental biology and clinical application. Research Immunology 146:628-637, 1995. 243. Pippin BA, Lotze MT. Cytokine Gene Therapy of Cancer in Aggarwal BB, Puri RK; Human Cytokines: Their Role in Disease and Therapy; Blackwell Science, Cambridge, pp675-688; 1995. 244. Lotze MT. Interleukin-2. In Growth Factors and Cytokines in Health and Disease. Ed. Derek LeRoith and Carolyn Bondy, JAI Press, Inc; Greenwich, CT; 199; pp1-47. 245. Tahara H, Lotze MT, Robbins PD, Storkus WJ, Zitvogel L. Clinical Protocol: IL-12 gene therapy using direct injection of tumors with genetically engineered autologous fibroblasts. Human Gene Therapy 6:1607-1624, 1995. 246. Leder GH, Oppenheim M, Rosenstein M, Lotze MT, Beger HG. Addition of IL-12 to low dose Interleukin 2 treatment improves antitumor efficacy in vivo. Z. Gastoenter 33:499-502, 1995. 247. Lotze MT. A new perspective: Cytokine Gene Therapy of Cancer. Cancer J from Scientific American 2:63-72, 1996. 248. Lotze MT, Kirkwood JM. Melanoma and other tumors of the skin. In, Kirkwood JM, Lotze MT, Yasko JM ed. Current Cancer Therapy, 2nd Ed.; Chapter 13, pp298-306; Churchill Livingston. Philadelphia, PA; 1996. 249. Lotze MT, Rubin JT. Biologic Therapeutics. In, Kirkwood JM, Lotze MT, Yasko JM ed. Current Cancer Therapy, 2nd Ed.; Chapter 4, pp66-86; Churchill Livingston. Philadelphia, PA; 1996. 250. Chang AE, Lotze MT, Pardoll DM. Mobilizing the body=s defenses against cancer.Patient Care 30:32-49, 1996. 42
  43. 43. 251. Pappo I, Lotze MT. Immunotherapy of lung cancer. In Landreneau R, editor. Thoracic Surgery, in press. 252. Elder EM, Lotze MT, Whiteside TL. Methods for generation of genetically-modified fibroblasts for immunotherapy of cancer. In Methods in Molecular Biology: Gene Therapy Protocols, Ed. Paul Robbins, in press. 253. Tahara H, Lotze MT. Cancer gene therapy using cytokine genes. Submitted. 254. Maeurer M, Zitvogel L, Storkus WJ, Lotze MT. Human intestinal v) T-cells respond exclusively to SEB, but not to SEA. Natural Immunity 14:188-97, 1995. 255. Zitvogel L, Robbins PF, Clarke MR, Abe R, Davis CG, and Lotze MT. B7.1 costimulation markedly enhances IL-12 mediated antitumor immunity in vivo. Eur Jl Immun.26:1335-1341, 1996. 256. Berman RM, Suzuki T, Tahara H, Narula SK, Robbins PD, Lotze MT. Systemic administration of cellular Interleukin-10 (cIL-10) induces an effective, specific and long-lived immune response against established tumors in mice. J Immunology 157:231-238, 1996. 257. Maeurer MJ, Martin DM, Storkus WJ, Lotze MT. Evidence for shared T-cell receptor usage in cytolytic T-cells recognizing HLA-A2 presented antigens shared by melanoma and melanocytes. Immunology Today 16:603-4, 1995. 258. Maeurer MJ, Martin DM,Walter W, Liu Kaihong, Zitvogel L, Haluszczak C, Rabinowich H, Duquesnoy R, Storkus WJ, Lotze MT. Vä1+ T-lymphocytes obtained from colorectal cancer patients recognize tumor cells of epithelial origin. J. Exp. Med, 183:1681-96, 1996. 259. Lotze MT. Cytokines and the Treatment of Cancer (Chapter 199; pp199.1-199.25). The Handbook of Experimental Immunology, 5th Edition, Ed Weir, Herzenberg, Herzenberg, and Blackwell. Blackwell Science, Inc.; Cambridge, MA; 1996. 260. Mayordomo JI, Loftus DJ, Sakamoto H, Lotze MT, Storkus WJ, Appella E, DeLeo AB. Therapy of murine tumors with dendritic cells pulsed with p53 wild type and mutant sequence peptides. J Exp Med 183:1357-1365, 1996. 261. Farhood H, Storkus WJ, Lotze MT. IL-12 and IL-2 synergistically induce IL-10 mRNA and protein in activated human lymphocytes. Annals of the New York Academy of Sciences 1996;795. 262. Tahara H, Zitvogel L, Storkus WJ, Robbins PD, Lotze MT. Murine models of cancer cytokine gene therapy using IL-12. Annals of the New York Academy of Sciences 1996;795:275-283. 263. Zitvogel L, Mayordomo JI, Storkus WJ, Tahara H, Robbins PD, Finn O, Lotze MT. Specific active immunotherapy for breast carcinoma: genetically modified tumor vaccines and peptide pulsed dendritic cell-based adoptive therapy. Preclinical studies and clinical trials. Colloquim - Scandinavian Breast Group; October 11-14, 1995; Published by Bristol Myers Squibb. 43
  44. 44. 264. Dookeran KA, Lotze MT, Sikora SS, Rao UNM. Pancreatic and periampullary carcinomas with epididymo-orchidic metastases. British Journal of Surgery 84:198-199, 1997. 265. Falo LD, Lotze MT. Cancer Vaccines, in Manual of Clinical Laboratory Immunology; 5th Edition. Chapter 133. Volume Editor: Everly Conway de Macario; Section Editor T. Whiteside. American Society for Microbiology Press, 1997. 266. Tzeng E, Shears LL, Lotze MT, Billiar TR. Gene Therapy. Current Prob. in Surgery 33:961- 1052, 1996. 267. Wasserman K, Rosenstein MM, Lotze MT. Regression of established tumors by combined systemic administration of Interleukin 12 and local irradiation. Unpublished. 268. Galon J, Gauchat J-F, Villiers C, Mazieres N, Spagnoli R, Storkus W, Lotze MT, Bonnefoy J-Y, Fridman WH, Sautes C. Soluble Fcã receptors bind to CR3 (CD11b/CD18) and CR4 (CD11c/CD18) complement receptors. J Immunology 157:1184-92, 1996. 269. Maeurer MJ, Martin DM, Gollin S, Castelli C, Swaney W, Robbins PD, Storkus WJ, Lotze MT. Recurrent melanoma exhibiting downregulation of the peptide transporter protein, TAP-1 and antigen-loss of the immunodominant antigen MART-1/Melan-A recognized by CD8+ cytotoxic T-lymphocytes. Journal of Clinical Investigation 98:1633-41, 1996. 270. Dumanian G, Llull R, Ramasastry S, Lotze MT, Greco R, Edington H. Abodominal wall dehiscence with enterocutaneous fistula: Management with split thickness skin grafts.American Journal of Surgery 172:332-4, 1996. 271. Rubin JT, Brumfield A, Dookeran KA, Lotze MT. Oil-based , sustained-release cytokine preparations: vehicles for regional therapy of cancer and tumor. Unpublished. 272. Rubin JT, Brumfield A, Dookeran K, and Lotze MT. Oil-based, sustained-release interleukin-2: a vehicle for regional therapy of cancer and tumor vaccines. Unpublished. 273. Mertz PM, Corcoran ML, McCluskey KM, Zhang Y, Wong HL, Lotze MT, DeWitt DL, Wahl SM, Wahl LM.Suppression of prostaglandin H synthase-2 induction in human monocytes by in vitro or in vivo administration of interleukin 4. Cellular Immunology 173:252-260, 1996. 274. Dookeran KA, Lotze MT, Brumfield A, Rubin JT. Generation of multiple hepatic metastases in a rat tumour model. Unpublished. 275. Zitvogel L, Corey S, Tim, Maeurer MJ, Couderc B, Rybak ME, Lotze MT, Donnenberg A. Interleukin-4-induced apoptosis of a ãä-T-cell leukemia: preclinical studies and in vivo application. Unpublished. 276. Goydos JS, Brumfield AM, Frezza E, Booth A, Lotze MT, Carty SE. Marked elevations in serum IL-6 levels in patients with cholangiocarcinoma. Annals of Surgery 227:398-404, 1998. 44

×